zoledronic acid has been researched along with Breast Cancer in 566 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (0.71) | 18.2507 |
| 2000's | 183 (32.33) | 29.6817 |
| 2010's | 338 (59.72) | 24.3611 |
| 2020's | 41 (7.24) | 2.80 |
| Authors | Studies |
|---|---|
| Lewis, K; Marongiu, A; Massey, L; Rider, A; Seesaghur, A; von Moos, R | 1 |
| Friedl, TWP; Janni, W; Rack, B | 1 |
| Sorscher, S | 1 |
| Aminizadeh, N; Hoseini-Shahrestanak, S; Jafarzadeh, A; Kalantari Khandani, B; Nemati, M; Rahimian, L | 1 |
| Balzarini, L; Berruti, A; Carrone, F; Cosentini, D; Farina, D; Lania, AG; Mazziotti, G; Pedersini, R; Pigni, S; Simoncini, EL; Torrisi, R; Vena, W; Zambelli, A | 1 |
| Akazawa, K; Horiguchi, J; Ishikawa, T; Kaise, H; Kohno, N; Kubota, T; Machida, Y; Miura, D; Narui, K; Suzuki, M; Taguchi, T; Takao, S; Tawaraya, K; Yamada, K | 1 |
| Götte, M; Lopes, CC; Onyeisi, JOS | 1 |
| Abe, K; Harata, S; Hongo, M; Igarashi, S; Kasama, F; Kasukawa, Y; Kudo, D; Miyakoshi, N; Nagasawa, H; Nozaka, K; Saito, H; Shoji, R; Tsuchie, H | 1 |
| Abdelhay, E; Binato, R; Crocamo, S; de Paula, B; Dos Santos, EC | 1 |
| Balic, M; Beltran-Bless, AA; Bjelic-Radisic, V; Clemons, MJ; Egle, D; Fesl, C; Fohler, H; Gampenrieder, SP; Gnant, M; Greil, R; Helfgott, R; Hilton, J; Hlauschek, D; Kacerovsky-Strobl, S; Pfeiler, G; Pond, GR; Rinnerthaler, G; Ritter, M; Singer, CF; Sölkner, L; Steger, GG; Suppan, C; Vandermeer, L | 1 |
| Liu, M; Qian, S; Wu, J; Xiao, J; Zeng, X | 1 |
| Chacko, G; Ganesan, S; George, MA; Kota, S; Kumar, S; Ohri, N; Omene, C; Toppmeyer, DL | 1 |
| Ishikawa, T | 1 |
| Deng, Y; Guo, X; Huang, P; Huang, X; Jiang, X; Lin, S; Liu, Y; Rao, X; Wang, H; Weng, X | 1 |
| Barcenas, CH; Bassett, R; Jayan, A; Raghavendra, AS | 1 |
| Baima, G; Bosso, I; Erovigni, F; Mussano, F; Pavone, L; Pedraza, R; Roato, I | 1 |
| Diel, I; Holtmann, L; Kerkmann, M; Link, H; Ohlmann, CH | 1 |
| Charehbili, A; de Groot, S; Dercksen, MW; Fiocco, M; Heijns, JB; Kessels, LW; Kroep, JR; Liefers, GJ; Meershoek-Klein Kranenbarg, E; Nortier, JWR; Pepels, MJAE; Pijl, H; Putter, H; Smit, VTHBM; van de Ven, S; van der Hoeven, JJM; van Laarhoven, HWM; van Warmerdam, LJC; Vriens, BEPJ | 1 |
| Kushima, C; Nakazato, M; Uchida, T; Yamaguchi, H; Yonekawa, T | 1 |
| Ahmed, GA; Farag, K; Mohamed, W; Yousof, O; Zabani, Y; Zekri, J | 1 |
| Bastin, S; Gamble, GD; Garratt, E; Horne, AM; Mihov, B; Reid, IR; Stewart, A | 1 |
| Aoun, M; Assi, T; Awada, A; Farhat, F; Kanj, A; Kattan, J; Tarabaih, M | 1 |
| Abrams, JS; Barlow, WE; Chew, HK; Clemons, M; Dakhil, SR; Dammann, KZ; Dees, EC; Elias, AD; Falkson, CI; Gralow, JR; Hayes, DF; Hershman, DL; Hortobagyi, GN; Ingle, JN; Lew, DL; Livingston, RB; M'iao, JL; Margolis, JH; Messino, MJ; Paterson, AHG; Schubert, MM; Stopeck, AT; Van Poznak, CH | 1 |
| Baum, T; Dieckmeyer, M; Einspieler, I; Karampinos, DC; Kirschke, JS; Metz, S; Rohrmeier, A; Rummeny, EJ; Ruschke, S; Schmidmayr, M; Seifert-Klauss, V; Syväri, J; Zimmer, C | 1 |
| Cao, W; Cao, X; Fan, C; Fu, Y; He, W; Hu, X; Kong, X; Li, C; Li, Q; Ling, D; Pang, Y; Qin, A; Sun, X; Wu, Z; Yang, C | 1 |
| Caruso, SR; Covas, DT; de Macedo, LD; De Santis, GC; Fernandes, TR; Ferrari, TC; Innocentini, LMAR; Orellana, MD; Ricz, HMA | 1 |
| Kajima, M; Makita, C; Manabe, Y; Matsuo, M; Matsuyama, K; Tanaka, H | 1 |
| Beidas, RS; Bekelman, JE; Ladage, VP; Mace, DS; Shulman, LN; Takvorian, SU; Wileyto, EP | 1 |
| Drumm, C; Grogan, L; Maguire, M; Mullally, W; O'Kane, M; Redmond, M; Woods, G | 1 |
| Boran, G; Dierking, I; Ege, D; Kamali, AR; Tavakoli, S | 1 |
| Cruz, C; Malamud, S; Miyashita, H | 1 |
| Sözel, H; Yilmaz, F | 1 |
| Coleman, R | 2 |
| Akpa, AA; Bathily, M; Berthe, D; Cisse, HL; Dao, S; Dembele, JP; Diabate, K; Diakite, A; Diallo, DA; Diarra, B; Diarra, IM; Fofana, Y; Guindo, I; Konate, M; Kone, AA; Kone, AC; Kone, AS; Kone, J; Minta, D; Ouattara, BZ; Sidibe, A; Sidibe, FM; Sidibe, S; Soumare, MD; Toloba, Y; Toure, BA | 1 |
| Aft, RL; Jallouk, AP; Paravastu, S; Weilbaecher, K | 1 |
| Brown, JE; D'Oronzo, S; Wood, S | 1 |
| Ahn, JH; Choi, IS; Choi, YJ; Jung, KH; Kang, SY; Kim, HJ; Kim, HS; Kim, HY; Kim, JW; Lee, KE; Lee, KH; Lee, S; Oh, HS; Park, IH; Park, KH; Park, KU; Park, YH; Seo, JH; Yoo, J | 1 |
| Ikeguchi, R; Kaizawa, Y; Matsuda, S; Noguchi, T; Ohta, S | 1 |
| Shapiro, CL | 1 |
| Amir, E; Desnoyers, A; Tannock, IF | 1 |
| Hakim, SG; Pries, R; Simon, R; Steller, D; Von Bialy, R | 1 |
| Hellig, J; Stevens, Z | 1 |
| Casimiro, S; Costa, L; Gomes, I; Vilhais, G | 1 |
| Chen, WL; Han, XH; Hu, QW; Li, JJ; Liu, S; Sun, ZP; Wang, JY; Zhang, S | 1 |
| Brezina, T; Cristino, J; Finek, J; Giannopoulou, C; Jandova, P; Kolek, M; Lothgren, M; Pásztor, B; Qian, Y | 1 |
| Fietz, T; Fleitz, A; Jänicke, M; Köhler, A; Marschner, N; Petersen, V; Schröder, J; Spring, L; Tesch, H | 1 |
| Blanchette, PS; Clemons, MJ; Dhesy-Thind, S; Dillmon, MS; Fletcher, GG; Frank, ES; Gandhi, S; Gupta, R; Mates, M; Moy, B; Van Poznak, CH; Vandenberg, T | 1 |
| Caldas, RJ; Maluf, G; Silva Santos, PS | 1 |
| Jun, JH | 1 |
| Bu, W; Cui, Z; Fan, Q; Han, X; He, XP; Ji, D; Qiao, H; Qin, A; Tang, T; Wang, T; Wang, Y; Yang, S; Yang, Y | 1 |
| Biskup, E; Cai, F; Vetter, M | 1 |
| Pu, H; Shi, L; Wang, J; Wang, Y; Zhang, M; Zhang, Q; Zhao, C | 1 |
| Gamper, J; Grunt, TW; Gschwantler-Kaulich, D; Mairhofer, M; Singer, CF; Tan, Y; Weingartshofer, S | 1 |
| Borah, BJ; Dusetzina, S; Foster, JC; Grubbs, SS; Himelstein, AL; Moriarty, JP; Novotny, PJ; Shapiro, CL | 1 |
| Alhashimi, M; Benyettou, F; Brandel, J; Mazher, J; O'Connor, M; Olsen, JC; Pasricha, R; Trabolsi, A; Traboulsi, H | 1 |
| Moy, B; Somerfield, MR; Van Poznak, C | 1 |
| Barlow, WE; Biermann, JS; Bosserman, LD; Clemons, MJ; Dhesy-Thind, SK; Dillmon, MS; Eisen, A; Frank, ES; Jagsi, R; Jimenez, R; Moy, B; Somerfield, MR; Theriault, RL; Van Poznak, C; Vandenberg, TA; Yee, GC | 1 |
| Costa, L; Ferreira, AR | 1 |
| Albanell, J; Bell, R; Cameron, D; Coleman, R; Dodwell, D; Gomis, RR; Gregory, W; Hall, A; Hanby, A; Jean-Mairet, J; Marshall, H; Rojo, F; Tercero, JC | 1 |
| Altrock, E; Bieback, K; Ghura, H; Groth, C; Hennenlotter, J; Jakob, F; Kuhlmann, JD; Link, T; Nakchbandi, IA; Rojewski, M; Rossnagl, S; Schott, S; Stenzl, A; Todenhöfer, T; Wimberger, P | 1 |
| Fukuoka, M; Hasegawa, Y; Miyatake, N; Ota, T; Tanaka, N; Tokunaga, M; Tsukuda, H | 1 |
| Lüftner, D; Niepel, D; Steger, GG | 1 |
| Goodwin, A; O'Carrigan, B; Pavlakis, N; Stockler, MR; Willson, ML; Wong, MH | 1 |
| Beelen, KJ; Bornebroek, M; Geijteman, ECT; Loef, M; Schweitzer, DH | 1 |
| Akazawa, K; Hasegawa, Y; Hayashi, M; Horiguchi, J; Ishikawa, T; Kohno, N; Miura, D; Tanino, H | 1 |
| Hasegawa, T; Uno, H; Wei, LJ | 1 |
| Himelstein, AL; Shapiro, CL | 1 |
| Hortobagyi, GN; Zheng, M | 1 |
| Gondo, N; Hamazaki, Y; Ikeda, T; Kanao, S; Masuda, N; Minato, N; Sugie, T; Sumi, E; Suzuki, E; Tada, H; Tanaka, Y; Toi, M; Uozumi, R; Yamagami, K; Yamauchi, A | 1 |
| Buehlmann, D; Grandjean, J; Rudin, M; Xandry, J | 1 |
| Borah, B; Moriarty, JP; Shapiro, CL | 1 |
| Bhatta, S; Buchanan, J; Hechmati, G; Kennedy, L | 1 |
| Cheng, J; Jia, X; Liu, G; Shao, Z; Shen, Z | 1 |
| Bell, R; Bertelli, G; Bowman, A; Brown, J; Burkinshaw, R; Cameron, D; Coleman, R; Gossiel, F; Gregory, W; Hanby, A; Hinsley, S; Maccon, K; Marshall, H; Rathbone, E; Shulver, H; Thandar, H | 1 |
| Bell, R; Brown, J; Cameron, D; Coleman, R; Dodwell, D; Hinsley, S; Marshall, H; Wilson, C | 1 |
| Cao, Q; Chen, X; Dong, C; Huang, J; Huang, P; Liao, R; Ren, G; Tan, Y; Wang, L; Wu, X | 1 |
| Bardia, A; Blackford, AL; Connolly, RM; Fetting, JH; Hayes, DF; Henry, NL; Jeter, SC; Miller, RS; Nguyen, A; Quinlan, K; Rosner, GL; Santa-Maria, CA; Slater, S; Snyder, C; Stearns, V; Storniolo, AM; Wolff, AC; Zorzi, J | 1 |
| Cao, XS; Cong, BB; Yu, ZY | 1 |
| Hadji, P; Hars, O; Kann, PH; Kyvernitakis, I; Thomasius, F | 1 |
| Berk, LB; Clarkson, JE; Clausen, CL; Cleary, SF; Demas, W; Derdel, JD; Kachnic, LA; Langer, C; Peters, CA; Pugh, SL; Rabinovitch, RA; Ramalingam, A; Rashtian, A; Seider, MJ; Tomblyn, M; Wyatt, G | 1 |
| Clézardin, P; Lelièvre, L; Magaud, L; Mathevet, P; Mouret-Reynier, MA; Raban, N; Roche, L; Tigaud, JD; Topart, D; Tubiana-Mathieu, N | 1 |
| Buller, J; Peters, F; Wenzel, C; Zinser, M; Zirk, M; Zöller, JE | 1 |
| Brown, JE; Cairns, DA; Coleman, RE; Dunning, MJ; Gahlaut, R; Hanby, AM; Marshall, H; Mavria, G; McMahon, K; Oliva, MR; Roberts, S; Selby, PJ; Shires, M; Speirs, V; Thygesen, H; Westbrook, JA; Wood, SL | 1 |
| Gui, K; Ji, W; Jiang, Z; Liang, G; Ma, J; Xiong, M; Yu, W; Yuan, F; Zeng, X; Zhang, C; Zhang, F; Zhao, M | 1 |
| Bhowmik, D; Body, JJ; De Courcy, J; Gatta, F; Hechmati, G; Henry, D; Qian, Y; Rider, A; von Moos, R | 1 |
| Dong, S; Feng, F; Qi, L; Sun, C; Tian, J; Wang, X; Yao, Y; Zhang, T; Zhou, C | 1 |
| Blok, EJ; Charehbili, A; de Groot, AF; Dekker-Ensink, NG; Engels, CC; Kroep, JR; Kuppen, PJK; Liefers, GJ; Meershoek-Klein Kranenbarg, E; Nortier, JWR; Putter, H; Smit, VTHBM; van de Velde, CJH; van der Burg, SH | 1 |
| Body, JJ; Costa, L; Gonzalez-Suarez, E; Niepel, D; Terpos, E; von Moos, R | 1 |
| Arenare, L; Barni, S; Cinieri, S; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Del Mastro, L; Di Rella, F; Fabbri, A; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Ibrahim, T; Iodice, G; Landi, G; Lauria, R; Mosconi, AM; Normanno, N; Nuzzo, F; Orditura, M; Pacilio, C; Perrone, F; Piccirillo, MC; Putzu, C; Ribecco, AS; Riccardi, F; Rossi, E; Simeon, V; Tinessa, V | 1 |
| Ge, K; Han, Y; Jin, Y; Liang, XJ; Liu, D; Liu, H; Sun, W; Yang, X; Zhang, H; Zhang, J; Zhou, G | 1 |
| Bava, U; Cornish, J; Lin, JM; Naot, D; Park, YE; Reid, IR | 1 |
| Gnant, M | 4 |
| Badalamenti, G; Bazan, V; Castellana, L; Galvano, A; Giuliana, G; Guadagni, F; Incorvaia, L; Pantano, F; Rizzo, S; Russo, A; Santini, D; Toia, F; Tonini, G; Vincenzi, B | 1 |
| Amadori, D; Fabbri, F; Ibrahim, T; Liverani, C; Mercatali, L; Sacanna, E; Zanoni, M; Zoli, W | 1 |
| Aft, R; Brufsky, AM; Coleman, RE; Eidtmann, H; Gnant, M; Lind, P; Mauri, D; Polyzos, NP; Swenson, K; Tevaarwerk, AJ; Valachis, A | 1 |
| Kaneko, M; Murata, T; Yamada, T; Yoshino, H | 1 |
| Delaissé, JM; Hansen, CT; Jakobsen, EH; Jørgensen, HB; Plesner, T; Søe, K | 1 |
| Irwin, B; Peppercorn, J | 1 |
| Coleman, RE; Cross, SS; Evans, A; Freeman, JV; Hatton, MQ; Holen, I; Ingram, CE; Jolley, IJ; Mori, S; Syddall, SP; Wilson, C; Winter, MC | 1 |
| Bastit, L; Guérif, S; Khemaies, S; Kouri, CE; Ktiouet, M; Lebret, T; Lortholary, A; Mouysset, JL; Murraciole, X | 1 |
| Akinci, MB; Aksoy, S; Altundag, K; Ozdemir, NY; Sendur, MA; Zengin, N | 1 |
| Aktas, B; Kasimir-Bauer, S; Kimmig, R; Lehmann, N; Tewes, M | 1 |
| Brodie, AH; Gilani, RA; Kazi, AA; Schech, AJ | 1 |
| Alhoniemi, E; Fagerlund, KM; Halleen, JM; Käkönen, R; Käkönen, SM; Mumberg, D; Rissanen, JP; Scholz, A; Suominen, MI; Ziegelbauer, K | 1 |
| López-Tarruella, S; Martin, M | 1 |
| Aglietta, M; Alessi, B; Amadori, D; Bertoldo, F; Bogani, P; Farina, G; Gaion, F; Gianni, L; Ibrahim, T; Ripamonti, CI; Rondena, R; Santini, D | 1 |
| Amadori, D; Fabbri, F; Gunelli, E; Ibrahim, T; Liverani, C; Maltoni, R; Mercatali, L; Ricci, M; Ricci, R; Scarpi, E; Serra, P; Zanoni, M; Zoli, W | 1 |
| Kuranishi, F; Ohno, T | 1 |
| Acham, S; Jakse, N; Kirnbauer, B; Lang, U; Luschin, G; Rugani, P | 1 |
| Agrawal, R; Bell, R; Brown, JE; Cameron, D; Chakraborti, P; Coleman, RE; Collinson, M; Jyothirmayi, R; Liversedge, V; Marshall, HC; Murden, GA; Rathbone, EJ; Spensley, S; Yuille, F | 1 |
| Aicher, WK; Fehm, T; Geiger, K; Kaiser, T; Klein, G; Teufel, I; Vater, Y | 1 |
| Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N | 1 |
| Body, JJ; Braun, A; Brown, JE; Chung, K; Cleeland, CS; Damyanov, D; Egerdie, B; Fallowfield, LJ; Marx, G; Palazzo, FG; Patrick, DL; Qian, Y; Stopeck, A; von Moos, R | 1 |
| Chang, CL; Chi, CW; Hsu, CC; Lan, YC; Lee, HC; Sung, MT; Tseng, LM; Wang, KC; Yin, PH | 1 |
| Binder, C; Bleckmann, A; Farhat, K; Hanisch, UK; Menck, K; Pukrop, T; Rietkötter, E; Schaffrinski, M; Schulz, M | 1 |
| Cueva, J; Lluch, A; Pérez-Fidalgo, JA; Ponce, J; Ruiz-Borrego, M | 1 |
| Barrett-Lee, P; Fenlon, D; Griffiths, G; Harrop, E; Hood, K; Morris, J; Murray, N; Nelson, A; Sampson, C; Wheatley, D | 1 |
| Banys, M; Becker, S; Fehm, T; Gebauer, G; Hirnle, P; Huober, J; Janni, W; Kraemer, B; Krawczyk, N; Lueck, HJ; Solomayer, EF; Wackwitz, B; Wallwiener, D | 1 |
| Han, K; Hu, H; Shen, Z; Sun, Y; Tang, L; Wang, Y; Wu, C; Yao, Y; Zhang, J | 1 |
| Body, JJ | 5 |
| Delaissé, JM; Hansen, CT; Jakobsen, EH; Plesner, T; Søe, K | 1 |
| Brown, J; Fullarton, JR; Palmieri, C | 1 |
| Brown, HK; Holen, I; Hughes, R; Nutter, F; Ottewell, PD; Rogers, TL; Vasiliadou, I; Wind, N | 1 |
| Abbadessa, G; Broggini, M; Chilà, R; Previdi, S; Ricci, F; Scolari, F | 1 |
| Fan, W; He, M; Zhang, X | 1 |
| Elahian, F; Lage, H; Mansouri, M; Mirzaei, SA; Mousavi, SS | 1 |
| Chang, KJ; Chao, TC; Chao, TY; Chen, DR; Chen, SC; Hou, MF; Huang, WT; Lee, KD; Rau, KM; Tai, CJ; Tseng, LM; Wang, HC; Yang, TL; Yeh, DC | 1 |
| Costa, L | 2 |
| Abraham, J; Barrett-Lee, P; Casbard, A; Coleman, R; Grieve, R; Griffiths, G; Hood, K; Murray, N; Simmonds, P; Timmins, H; Wheatley, D | 1 |
| Balakumaran, A; Chung, K; Dodge, T; Edelsberg, J; Glass, AG; Lamerato, L; Lopez, A; Oster, G; Richert-Boe, KE; Richhariya, A; Wolff, GG | 1 |
| Enomoto, T; Kikuchi, M; Kosaka, Y; Minatani, N; Nishimiya, H; Sengoku, N; Tanino, H; Waraya, M; Watanabe, M | 1 |
| Gerngroß, C; Hohlweg-Majert, B; Koerdt, S; Otto, S; Pautke, C; Ristow, M; Ristow, O; Schuster, R; Schwaiger, M | 1 |
| Andreis, D; Bertoni, R; Bonelli, M; Bottini, A; Brugnoli, G; Cappelletti, M; Ferrero, G; Foroni, C; Fox, SB; Fumarola, C; Generali, D; Maldotti, M; Milan, M; Parissenti, A; Petronini, PG; Pritzker, K; Pritzker, L; Santini, D; Strina, C; Takano, E; Venturini, S; Zanoni, V | 1 |
| Gerngroß, C; Hahnefeld, L; Hohlweg-Majert, B; Jansen, H; Kehl, V; Otto, S; Pautke, C; Ristow, O; Schwaiger, M | 1 |
| Baier, M; Beckmann, MW; Berghorn, M; Fasching, PA; Grab, D; Hanf, V; Hauschild, M; Jud, SM; Kahlert, S; Kreienberg, R; Krocker, J; Kühn, T; Kümmel, S; Lux, MP; Müller, T; Muth, M; Paepke, S; Schulz-Wendtland, R; Schütte, M; Stickeler, E; Wackwitz, B; Warm, M; Wolf, C | 1 |
| Baier, M; Bauer, M; Birkholz, K; Hadji, P; Kauka, A; Muth, M; Ziller, M | 1 |
| Guo, RT; Li, XL; Li, Y; Luan, JW; Nie, D; Wu, J; You, QS; Zhang, LP | 1 |
| Baier, M; Birkholz, K; Hadji, P; Kann, P; Kauka, A; Muth, M; Ziller, M | 1 |
| Della Coletta, R; dos Santos-Silva, AR; Flores, IL; Lopes, MA; Vargas, PA | 1 |
| Gerngroß, C; Hahnefeld, L; Hohlweg-Majert, B; Jansen, H; Kehl, V; Koerdt, S; Otto, S; Pautke, C; Ristow, O; Schwaiger, M | 1 |
| Charehbili, A; Dercksen, M; Hamdy, NA; Heijns, JB; Kessels, L; Kroep, JR; Liefers, GJ; Maartense, E; Meershoek-Klein Kranenbarg, E; Nortier, JW; Pepels, MJ; Putter, H; Smit, VT; van de Velde, CJ; van de Ven, S; van Laarhoven, HW; van Leeuwen-Stok, AE; van Warmerdam, LJ; Vriens, B; Wasser, MN | 1 |
| Aono, M; Hayashi, K; Kazuki, K; Shintani, K | 1 |
| Han, X; Liu, S; Sun, Z; Wu, C; Yang, S; Ye, Y | 1 |
| Brown, HK; Croucher, PI; Eaton, CL; Fowles, CA; Holen, I; Ottewell, PD; Reeves, KJ; Wang, N | 1 |
| Angelis, CD; Burke, N; Giotis, A; Goeree, R; Habib, M; Hopkins, RB; Pasetka, M; Xie, F | 1 |
| Geist, A; Grimm, M; Hoefert, S; Krimmel, M; Reinert, S; Sharghi, F | 1 |
| Aguilar-Salvatierra, A; Arribas-Fernández, MC; Boquete-Castro, A; Botticelli, D; Calvo-Guirado, JL; Fernández-Guerrero, M; Gómez-Moreno, G; Guardia, J | 1 |
| Brown, HK; Dear, TN; Haider, MT; Holen, I; Hunter, K | 1 |
| Barrett-Lee, P; Bell, R; Burkinshaw, R; Cameron, D; Coleman, R; Dodwell, D; Gil, M; Grieve, R; Hinsley, S; Keane, M; Liversedge, V; Marshall, H; Rathbone, E; Ritchie, D; Wilson, C | 1 |
| Chan, KC; Fleisher, KE; Friedman, KP; Glickman, RS; Gupta, V; Janal, M; Mourtzikos, KA; Raad, RA; Rakheja, R | 1 |
| Antón, A; Arizcuma, A; Barnadas, A; Calvo, L; Chacón, JI; Codes, M; Crespo, C; de Juan, A; de la Piedra, C; Gavilá, J; Gómez, P; Heras, L; Luque, M; Mahillo-Fernández, I; Manso, L; Margelí, M; Martin-Fernández, M; Martinez, P; Meseguer, C; Murias, A; Perelló, A; Pérez, D; Ruiz-Borrego, M; Salvador, J; Seguí, MÁ; Tusquets, I; Zamora, P | 1 |
| Ross, JS | 1 |
| Barrett-Connor, E; Bauer, DC; Black, DM; Cauley, JA; Cummings, SR; Ensrud, KE; Hue, TF | 1 |
| Pautke, C; Ristow, O | 1 |
| Charehbili, A; Kroep, JR; Liefers, GJ; Meershoek-Klein Kranenbarg, WM; Nortier, JW; Putter, H; Smit, VT; van de Velde, CJ; van Leeuwen-Stok, AE; Wasser, MN | 1 |
| Akens, MK; Schwock, J; Whyne, CM; Wilson, BC; Wise-Milestone, L; Won, E; Yee, AJ | 1 |
| Ngarmukos, S; Tanavalee, A; Tantavisut, S; Thanakit, V; Wangroongsub, Y; Wilairatana, V | 1 |
| Brufsky, A; Mathew, A | 1 |
| Felsenberg, D; Gabbert, TI; Hoffmeister, B | 1 |
| Albert, US; Baier-Ebert, M; Hadji, P; Kalder, M; Kyvernitakis, I | 1 |
| Balic, M; Bartsch, R; Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Fitzal, F; Gnant, M; Greil, R; Hochreiner, G; Jakesz, R; Knauer, M; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Moik, M; Ploner, F; Seifert, M; Selim, U; Sevelda, P; Steger, G; Stoeger, H; Taucher, S; Wette, V | 1 |
| Ikeda, T; Minato, N; Shimizu, A; Sugie, T; Sumi, E; Suzuki, E; Tada, H; Tanaka, Y; Teramukai, S; Toi, M; Yoshimura, K | 1 |
| Evdokiou, A; Fung, KP; Gao, S; Ko, CH; Lau, CB; Lee, JK; Leung, PC; Li, G; Luo, KW; Yue, GG | 1 |
| Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S | 1 |
| Auriola, S; Määttä, J; Mönkkönen, J; Sousa, S | 1 |
| Buccione, R; Chaudhari, KR; Hyttinen, JM; Kaarniranta, K; Khandelwal, VK; Mitrofan, LM; Mönkkönen, J; Ravingerová, T | 1 |
| Abe, Y; Hirai, R; Ikeda, E; Kashima, H; Kuroda, M; Kurosaki, T; Miyahara, K; Moriyama, S; Takagi, S; Tsuji, H; Yamano, T; Yoshitomi, S | 1 |
| Atherton, P; Burger, K; Diekmann, B; Dueck, AC; Hines, S; Liu, H; Loprinzi, CL; Novotny, P; Perez, EA; Singh, J; Sloan, JA; Tan, A; Zhao, X | 1 |
| Bohlmann, MK; Luedders, DW; Rody, A; Steinhoff, J; Thill, M | 1 |
| Blackwell, K; Harnden, K | 1 |
| Coleman, RE; Holen, I; Ottewell, P; Wilson, C | 1 |
| Cheng, J; Hong, Q; Jia, X; Lei, L; Li, D; Li, J; Liu, G; Mo, M; Shao, Z; Shen, Z; Wang, Y | 1 |
| Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND | 1 |
| Arai, N; Hattori, Y; Inoue, S; Noguchi, M; Takashina, M; Tomihara, K | 1 |
| Ishii, S; Kikuchi, K; Miyajima, M; Sakuma, K; Shishido, F | 1 |
| Agacayak, F; Alco, G; Celebi, F; Demir, G; Eralp, Y; Erdogan, Z; Ilgun, S; Okkan, S; Ordu, C; Ozmen, V; Pilanci, KN; Sarsenov, D; Tecimer, C | 1 |
| Body, JJ; Braun, A; Diel, IJ; Feng, A; Goldwasser, F; Spencer, A; Steger, G; Stopeck, AT; Vadhan-Raj, S; von Moos, R | 1 |
| Dessapt, R; Dolbecq, A; Haouas, M; Kubo, T; Marrot, J; Mialane, P; Oldfield, E; Rivière, E; Rousseau, G; Saad, A; Serier-Brault, H; Taulelle, F; Zhu, W | 1 |
| Arjaans, M; de Vries, EG; Nienhuis, HH; Schröder, CP; Timmer-Bosscha, H | 1 |
| Fan, QM; Han, XG; Qiao, H; Qin, A; Tang, TT; Wang, TY; Wang, YG; Yan, W | 1 |
| Atherton, PJ; Dakhil, SR; Hines, SL; Lafky, JM; Loprinzi, CL; Majithia, N; Olson, J; Perez, EA; Wagner-Johnston, N | 1 |
| Ding, D; Du, Y; He, ZQ; Jia, XH; Ma, XB; Mao, D; Qiu, JD; Shang, WT; Tian, J; Wang, ZL | 1 |
| Arellano, J; Body, JJ; Braun, A; Brown, JE; Carducci, M; Diel, I; Fizazi, K; Fujiwara, Y; Karsh, L; Kueppers, F; Maniar, T; Martín, M; Paterson, A; Shore, N; Sieber, P; Stopeck, AT; Tonkin, K; Wang, H; Yardley, D | 1 |
| Cohen, PR | 1 |
| Atmaca, H; Bozkurt, E; Erdogan, AP; Gursoy, P; Karaca, B; Şanlı, UA; Sezgin, C; Surmeli, Z; Uslu, R; Uzunoglu, S | 1 |
| Browne, AJ; Göbel, A; Hofbauer, LC; Rachner, TD; Rauner, M; Thiele, S | 1 |
| Clézardin, P; Gineyts, E; Melodelima, D; Ngo, J; Roux, JP; Tardoski, S | 1 |
| Eaton, CL; Evans, CA; Fowles, A; Holen, I; Nutter, F; Ottewell, PD; Walker, M | 1 |
| Akazawa, K; Hasegawa, Y; Hayashi, M; Horiguchi, J; Ishikawa, T; Kim, SJ; Kohno, N; Konishi, M; Kubota, T; Miura, D; Miyashita, M; Shigeoka, Y; Suzuki, M; Taguchi, T; Takao, S; Tanino, H; Yamagami, K | 1 |
| Bouganim, N; Cella, D; Clemons, M; Dent, S; Dranitsaris, G; Gertler, S; Jacobs, C; Kuchuk, I; Mazzarello, S; Simos, S; Smith, S; Song, X; Vandermeer, L; Verma, S | 1 |
| Aapro, M; Albert, US; Bergh, J; Body, JJ; Cameron, D; Clézardin, P; Coleman, RE; Conte, PF; Cortes, J; Costa, L; Di Leo, A; Diel, I; Dodwell, D; Ejlertsen, B; Gnant, M; Gray, R; Hadji, P; Harbeck, N; Holen, I; Kaufmann, M; Markopoulos, C; Martin, M; Powles, TJ; Santini, D; Smith, I; Thurlimann, B; Untch, M; Wilson, C | 1 |
| Aft, RL; Akazawa, K; Charehbili, A; Coleman, RE; Hasegawa, Y; Hinsley, S; Kohno, N; Kroep, JR; Liefers, GJ; Nortier, JWR; Putter, H; Weilbaecher, K; Winter, MC | 1 |
| Banks, RE; Brown, JE; Cairns, DA; Coleman, RE; Hanby, AM; Holen, I; Marshall, H; Ottewell, PD; Peng, J; Selby, PJ; Speirs, V; Westbrook, JA; Wood, SL | 1 |
| Bell, R; Cameron, DA; Coleman, RE; Gregory, WM; Howard, DR; Smye, SW; Twelves, CJ | 1 |
| Fan, QM; Han, XG; Liu, XQ; Qiao, H; Qin, A; Tang, TT; Wang, TY; Wang, YG; Yu, ZF | 1 |
| Bettinsoli, P; Bodei, S; Bonini, SA; Bottini, A; Fragni, M; Generali, D; Memo, M; Sigala, S; Spano, PF | 1 |
| Auriola, S; Määttä, JA; Mönkkönen, J; Zlatev, HP | 1 |
| Browne, AJ; Göbel, A; Hofbauer, LC; Rachner, TD; Rauner, M; Thiele, S; Zinna, VM | 1 |
| Fujimoto, M; Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kinoshita, F; Kodaira, M; Shimizu, C; Takahashi, N; Tamura, K; Tanaka, R; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Caraglia, M; De Rosa, G; Desiderio, V; Gazzano, E; Ghigo, D; Giordano, A; Kopecka, J; Lusa, S; Pinzòn-Daza, ML; Porto, S; Riganti, C; Salzano, G | 1 |
| Ea, HK; Paycha, F; Poiroux, L; Polivka, M | 1 |
| Higuchi, T; Imamura, M; Miyagawa, Y; Miyoshi, Y; Murase, K; Nishimukai, A; Ozawa, H; Takatsuka, Y; Yanai, A | 1 |
| Amodeo, V; Barraco, N; Bazan, V; Castiglia, M; Castorina, S; Fanale, D; Giordano, A; Incorvaia, L; Insalaco, L; Rizzo, S; Russo, A; Santini, D | 1 |
| Blackwell, K; Brewster, AM; Costelloe, CM; Hood, I; Hortobagyi, GN; Ibrahim, NK; Koenig, KB; Mitri, Z; Moulder-Thompson, S; Nanda, R; Rimawi, MF; Van Poznak, C; Wei, C | 1 |
| Abdel-Rahman, O | 1 |
| Blohmer, JU; Burchardi, N; Costa, SD; Denkert, C; Dubsky, P; Fasching, PA; Gerber, B; Hanusch, C; Hilfrich, J; Huober, J; Jackisch, C; Kümmel, S; Loibl, S; Mehta, K; Paepke, S; Rezai, M; Schneeweiss, A; Tesch, H; Untch, M; von Minckwitz, G; Zahm, DM | 1 |
| Bonanini, M; Fornaini, C; Giovannacci, I; Manfredi, M; Meleti, M; Merigo, E; Vescovi, P | 1 |
| Chang, B; Du, SX; Hu, QX; Li, XD; Lin, FX; Xie, D; Yu, GY; Zheng, GZ | 1 |
| Alberts, DS; Greene, MH; Hibler, EA; Kauderer, J; Rodriguez, GC | 1 |
| Chien, S; Guo, F; Jiang, P; Kesari, S; Mukthavaram, R; Nomura, N; Pingle, SC; Teng, D; Zhang, P | 1 |
| Alho, I; Ali, S; Casimiro, S; Costa, L; Faria, M; Ferreira, AR; Leitzel, K; Lipton, A; Matias, M; Shan, N | 1 |
| Baklaushev, VP; Burenkov, MS; Chekhonin, VP; Grinenko, NF; Gubskii, IL; Ivanova, NV; Rabinovich, EZ; Yusubalieva, GM | 1 |
| Ceausu, I; Depypere, H; Lambrinoudaki, I; Mueck, A; Pérez-López, FR; Rees, M; Senturk, LM; Simoncini, T; Stevenson, JC; Stute, P; Trémollieres, FA; van der Schouw, YT | 1 |
| Andreadis, C; Antoniades, K; Kouvelas, D; Kyrgidis, A; Lagoudaki, R; Yavropoulou, MP | 1 |
| Atkins, G; DeNichilo, MO; Evdokiou, A; Findlay, D; Hay, S; Ingman, W; Liapis, V; Panagopoulos, V; Ponomarev, V; Zannettino, A; Zinonos, I; Zysk, A | 1 |
| Chen, CY; Chen, SC; Lin, TM; Liu, H; Lo, JL; Wang, SH | 1 |
| Foster, JC; Go, RS; Grubbs, SS; Himelstein, AL; Khatcheressian, JL; Loprinzi, CL; Novotny, PJ; O'Connor, T; O'Mara, A; Qin, R; Roberts, JD; Seisler, DK; Shapiro, CL; Velasco, MR; Weckstein, D | 1 |
| Guise, TA; Harhash, AA; John, SK; Kozlow, WM; Marks, AR; Mohammad, KS; Murthy, S; Niewolna, M; Regan, JN; She, Y; Waning, DL; Wright, LE | 1 |
| Bassa, P; Capdevila, L; Garcia, JR; Pérez, C; Ramos, F; Valenti, V | 1 |
| Laghezza, A; Lynch, CC; Neuger, AM; Sansil, SS; Shay, G; Soliman, H; Tauro, M; Tortorella, P | 1 |
| Fornier, MN | 1 |
| Chew, H; Dakhil, SR; Gradishar, WJ; Haley, BB; Harker, WG; Hortobagyi, GN; Lipton, A; Mohanlal, R; Sauter, N; Van Poznak, C; Zheng, M | 1 |
| Agrillo, A; Corsi, A; Riminucci, M; Ungari, C | 1 |
| Allocca, G; Brown, NJ; DeCristo, MJ; Haider, MT; Holen, I; McAllister, SS; Silver, DP; Ubellacker, JM | 1 |
| Barrett-Lee, P; Casbard, A; Farewell, D; Gillespie, D; Hawthorne, AB; Hood, K; Hurt, C; Murray, N; Probert, C; Stenson, R | 1 |
| Duan, Z; Fang, S; Giordano, SH; Goodwin, JS; Hortobagyi, GN; Kuo, YF | 1 |
| Brufsky, A; Bundred, N; Coleman, R; Ericson, S; Hadji, P; Jin, L; Lambert-Falls, R; Mena, R; Perez, EA; Schenk, N | 1 |
| Andreadis, C; Boukovinas, I; Koloutsos, G; Kyrgidis, A; Patrikidou, A; Teleioudis, Z; Triaridis, S; Vahtsevanos, K | 1 |
| Clezardin, P; Coleman, RE; Cross, S; Deux, B; Holen, I; Mönkkönen, H; Ottewell, PD | 1 |
| Hampton, T | 1 |
| Brafman, L; Cremers, S; Crew, KD; Cucchiara, G; Hershman, DL; Irani, D; McMahon, DJ; Shane, E | 1 |
| Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P | 1 |
| Barghout, V; Hatoum, HT; Lin, SJ; Lipton, A; Smith, MR | 1 |
| Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH | 1 |
| Ariyoshi, N; Hosoi, A; Kakimi, K; Kondo, M; Nakagawa, K; Nakajima, J; Noguchi, A; Sakuta, K; Sato, K; Sato, S; Shiraishi, K; Yoshida, Y | 1 |
| Buijs, JT; Löwik, CW; Papapoulos, SE; Que, I; van der Pluijm, G | 1 |
| Kyrgidis, A; Triaridis, S | 1 |
| Cheng, J; Wu, G; Wu, HG; Xue, J | 1 |
| Lyseng-Williamson, KA | 1 |
| Fricker, J | 1 |
| Banys, M; Beck, V; Fehm, T; Hairass, M; Krimmel, M; Lipp, HP; Reinert, S; Solomayer, EF; Wallwiener, D | 1 |
| Arita, K; Hiranuma, S; Kuramochi, J; Kurokawa, T; Matsumoto, A; Sanada, K; Takiguchi, N; Tanaka, Y; Usui, S | 1 |
| Cree, IA; Dexel, S; Fernando, A; Glaysher, S; Knight, LA; Kurbacher, CM; Reichelt, R; Reinhold, U | 1 |
| Almojaly, SA; Berk, J; Dziak, R; Goodloe Iii, S; Margarone Iii, J; Rao, MV; Sullivan, M | 1 |
| Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Fitzal, F; Fridrik, M; Gnant, M; Greil, R; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rücklinger, E; Samonigg, H; Schippinger, W; Seifert, M; Steger, G; Stierer, M; Tausch, C | 1 |
| Alberts, S; Dentchev, T; Hines, SL; Johnson, DB; Kahanic, S; Liu, H; Loprinzi, CL; Mazurczak, MA; Mincey, B; Nikcevich, DA; Perez, EA; Schaefer, PL; Sloan, JA | 1 |
| Amir, E; Clemons, M; Fralick, M; Freedman, OC; Hardisty, M; Kumar, R; Whyne, C | 1 |
| Bertoldo, F; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Botti, G; Chiodini, P; D'Aiuto, G; De Feo, G; De Maio, E; de Matteis, A; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E | 1 |
| Amir, E; Clemons, MJ; Dranitsaris, G; Simmons, CE; Trinkaus, M | 1 |
| Bosserman, LD; Brufsky, AM; Caradonna, RR; Ericson, SG; Haley, BB; Jin, L; Jones, CM; Moore, HC; Perez, EA; Warsi, GM | 1 |
| Ajarim, D; Al-Hussein, K; Al-Sayed, A; Al-Sulaiman, A; Aljurf, MD; Alsharif, F; Alzahrani, H; Gaafar, A; Iqniebi, A; Manogaran, PS; Mohamed, GE; Mohareb, F; Tabakhi, A | 1 |
| Coleman, RE | 5 |
| Wenz, F | 1 |
| Akmansu, M; Atahan, L; Cengiz, M; Dinçer, M; Engin, K; Gündoğ, M; Haydaroğlu, A; Hayran, M; Kaplan, B; Korcum, AF; Ozkan, M; Sengöz, M; Yazici, G; Yildiz, F | 1 |
| Aebi, S; Gelber, RD | 1 |
| De Luca, A; Normanno, N | 1 |
| Gerber, B; Reimer, T | 1 |
| Berruti, A; Buttigliero, C; Dogliotti, L | 1 |
| Dong, PW; Li, LN | 1 |
| Benad, P; Bornhäuser, M; Ebert, R; Ellenrieder, V; Hofbauer, LC; Jakob, F; Rachner, TD; Schoppet, M; Singh, SK | 1 |
| Coleman, RE; Cross, SS; Evans, CA; Holen, I; Lefley, DV; Ottewell, PD | 1 |
| Alameda Hernando, C; Díaz Guardiola, P; Guijarro de Armas, G; Iglesias Bolaños, P; Pavón de Paz, I; Vega Piñero, B | 1 |
| Chanda, D; Folks, K; Szafran, AA; Wang, D; Warram, J; Zinn, KR | 1 |
| Campbell-Baird, C; Costa, L; Demers, L; Harvey, H; Kim, C; Lipton, A | 1 |
| Coleman, RE; Winter, MC | 2 |
| Doggrell, SA | 1 |
| Coleman, RE; Evans, CA; Holen, I; Lefley, DV; Ottewell, PD; Woodward, JK | 1 |
| Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K | 1 |
| Auriola, S; Mönkkönen, H; Mönkkönen, J; Räikkönen, J | 1 |
| Albert, U; Hadji, P; Kalder, M; Maskow, C; Ziller, M | 1 |
| Castellana, MA; Gasparini, G; Longo, R | 1 |
| Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A | 1 |
| Crawford, BS; Kraut, EH; McNulty, RM; Turowski, RC | 1 |
| Botteman, MF; Heeg, BMS; Kaura, S; Logman, JFS; van Hout, BA | 1 |
| Brown, HK; Coleman, RE; Holen, I; Ottewell, PD | 1 |
| Awad, D; Brafman, L; Cremers, S; Crew, KD; Hershman, DL; McMahon, DJ; Shane, E; Shao, T | 1 |
| Chetty, U; Wishart, GC | 1 |
| Smith, IE | 1 |
| Akens, MK; Burch, S; Whyne, CM; Wilson, BC; Wise-Milestone, L; Won, E; Yee, AJ | 1 |
| Atherton, PJ; Dakhil, SR; Dalton, RJ; Hines, SL; Johnson, DB; Loprinzi, CL; Mattar, BI; Perez, EA; Reddy, PS; Sloan, JA | 1 |
| Berardi, R; Bertoldo, F; Calipari, N; Fratto, ME; Ibrahim, T; Ottaviani, D; Sabbatini, R; Santini, D; Virzi, V | 1 |
| Sugie, T; Tanaka, Y; Toi, M | 1 |
| Divgi, C; Grewal, RK; Hudis, CA; Larson, S; Mak, AF; Modi, S; Morris, PG; Patil, S; Poznak, CV | 1 |
| Grieve, RJ; Hamilton, E; Hickish, T; Houston, S; Percival, F | 1 |
| Fossion, E; Huizing, MT; Van den Wyngaert, T; Vermorken, JB | 1 |
| Coleman, RE; Holen, I; Neville-Webbe, HL | 1 |
| Bell, R; Burkinshaw, R; Cameron, D; Coleman, RE; Dodwell, D; Gil, M; Keane, MM; Marshall, SJ; Passos-Coelho, JL; Ritchie, D; Thorpe, H; Wheatley, D; Winter, MC | 1 |
| Amir, E; Clemons, M; Josse, R; Ocaña, A; Seruga, B | 1 |
| Aft, R; Ali, A; Chavez-MacGregor, M; Diemer, K; Dietz, J; Eberlein, T; Ellis, M; Fracasso, PM; Gillanders, W; Herrmann, V; Kuo, S; Ma, C; Mortimer, J; Naughton, M; Pluard, T; Shannon, W; Taylor, M; Trinkaus, K; Watson, M; Weilbaecher, K; Weiss, P; Ylagan, L; Zhai, J; Zoberi, I | 1 |
| Campisi, G; Colella, G; Fusco, V; Loidoris, A; Vescovi, P | 1 |
| Fox, KR | 1 |
| Harbeck, N; Thürlimann, B; von Minckwitz, G | 1 |
| Aebi, S; Diel, I | 1 |
| Eidtmann, H; Gnant, M | 1 |
| Bundred, N; Coleman, R; Davidson, N; de Boer, R; Eidtmann, H; Llombart-Cussac, A; Miller, J; Neven, P; Schenk, N; von Minckwitz, G | 1 |
| Buccheri, S; Caccamo, N; Cicero, G; D'Asaro, M; Dieli, F; Eberl, M; Guggino, G; Hayday, AC; La Mendola, C; Meraviglia, S; Orlando, V; Roberts, A; Scarpa, F; Stassi, G; Todaro, M; Vermijlen, D | 1 |
| Dai, J; Keller, ET; Keller, JM; Lu, Y; Mizokami, A; Yu, C; Zhang, J | 1 |
| Bäuerle, T; Komljenovic, D; Merz, M; Semmler, W; Zwick, S | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Costa, L; Lipton, A | 1 |
| Friese, K; Genss, EM; Heinrigs, M; Janni, W; Jückstock, J; Rack, B; Rammel, G; Schindlbeck, C; Schoberth, A; Sommer, H; Strobl, B; Zwingers, T | 1 |
| Beckmann, MW; Gnant, M; Jonat, W; Kreienberg, R; Lux, MP; Reichelt, C; Thiel, FC; Wallwiener, D | 1 |
| Fujiwara, I; Ichida, M; Matsumoto, M; Mizuta, M; Mizuta, N; Nishiyama, A; Ohashi, M; Sakaguchi, K; Umeda, Y | 1 |
| Brufsky, AM | 3 |
| Van Poznak, C | 1 |
| Delea, TE; Gnant, M; Kaura, S; Sofrygin, O; Taneja, C | 1 |
| Clézardin, P; Contié, S; Garnero, P; Litvin, J; Voorzanger-Rousselot, N | 1 |
| Hayashi, N; Hortobagyi, GN; Onishi, T; Theriault, RL; Ueno, NT | 1 |
| Aapro, M; Coleman, R; Gnant, M; Hadji, P; Lipton, A | 1 |
| Deuber, HJ; Theiss, F | 1 |
| Chen, J; Guo, H; Guo, L; Guo, X; Hu, X; Ragaz, J; Shao, Z; Wang, Z; Wu, J; Xu, X; Zhao, X; Zhu, B; Zhu, J | 1 |
| Jahanzeb, M; Mahtani, R | 1 |
| Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, HJ; Kim, JE; Kim, SB; Kim, SY; Lee, KS; Lee, MH; Park, YH; Ro, JS | 1 |
| Altundag, K; Arslan, C; Tonyali, O | 1 |
| Aapro, M; Costa, L; Saad, F | 1 |
| Tang, SC | 1 |
| Body, JJ; Braun, A; Dansey, R; de Boer, RH; Fan, M; Fujiwara, Y; Jiang, Q; Jun, S; Lichinitser, M; Lipton, A; Steger, GG; Stopeck, AT; Tonkin, K; Viniegra, M; Yardley, DA | 1 |
| Chiplunkar, SV; Dhar, S | 1 |
| Berd, Y; He, W; Jensen, AB; Lombardi, A; Mehta, A; Ramirez, G; Song, Y; Wang, H; Wynne, C | 1 |
| Abrams, J; Bhargaval, A; Graff, JJ; Nahleh, Z; Nirmal, K | 1 |
| Binkley, N; Eickhoff, J; Leal, T; Love, R; Mulkerin, D; Parrot, B; Stewart, J; Tevaarwerk, A | 1 |
| Hadji, P | 2 |
| Coleman, R; Cook, R; Hirsh, V; Lipton, A; Major, P | 1 |
| Arduino, PG; Battaglio, C; Berardi, D; Broccoletti, R; Chiecchio, A; Donadio, M; Gandolfo, S; Menegatti, E; Mozzati, M; Scoletta, M; Scully, C; Vandone, AM | 1 |
| Archer, L; Burstein, HJ; Halabi, S; Hars, V; Hudis, C; Isaacs, C; Kirshner, J; Paskett, E; Schilsky, R; Shapiro, CL; Sikov, W; Weckstein, D; Winer, E | 1 |
| Barlow, WE; Biermann, JS; Bosserman, LD; Geoghegan, C; Hillner, BE; Janjan, NA; Temin, S; Theriault, RL; Van Poznak, CH; Von Roenn, JH; Yee, GC; Zuckerman, DS | 1 |
| Voelker, R | 1 |
| van der Pluijm, G | 1 |
| Berenson, J; Dimopoulos, MA; Terpos, E | 1 |
| Morgan, GJ | 1 |
| Taguchi, T | 1 |
| Busby, R; Espinoza, I; Liu, H; Lupu, R | 1 |
| Barrett-Lee, PJ; Bell, R; Brown, J; Burkinshaw, R; Cameron, D; Coleman, R; Davies, C; Dodwell, D; Gil, M; Grieve, RJ; Houston, SJ; Keane, M; Thorpe, H; Woodward, E | 1 |
| Aapro, MS; Body, JJ; Brufsky, A; Bundred, NJ; Coleman, RE; Gnant, M; Guise, T; Hadji, P; Lipton, A | 1 |
| Robinson, F | 1 |
| Greil, R; Mlineritsch, B; Ressler, S | 1 |
| Chiu, CF; Lin, PH; Lu, YS | 1 |
| Aapro, MS | 1 |
| Bargagli, G; Francini, E; Francini, F; Miano, ST; Pascucci, A; Petrioli, R; Ruggiero, G | 1 |
| Imamura, F; Sakai, D; Sugimoto, N; Yagi, T; Yoshinami, T | 1 |
| De Luca, A; Gallo, M; Lamura, L; Normanno, N | 1 |
| D'Alessio, A; Daniele, G; De Luca, A; Gallo, M; Giordano, P; Lamura, L; Maiello, MR; Normanno, N; Pergameno, M; Perrone, F | 1 |
| Kayata, Y; Kikawa, Y; Nakamoto, Y; Ogata, M; Yamamoto, M | 1 |
| Chen, J; Liu, ZY; Zhao, LJ | 1 |
| Fehm, T; Kootz, B; Neubauer, H; Schott, S; Seeger, H; Wallwiener, M | 1 |
| Bauer, JS; Beck, N; Eitner, S; Kiefer, J; Stockmann, P; Wichmann, M | 1 |
| Barth, P; Baumgart, S; Ellenrieder, V; Fernandez-Zapico, ME; Gress, TM; Hofbauer, LC; König, AO; Lomberk, G; Reutlinger, K; Singh, G; Singh, SK; Urrutia, R | 1 |
| Bauernhofer, T; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Forsthuber, EP; Gnant, M; Greil, R; Heck, D; Hochreiner, G; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Menzel, C; Mlineritsch, B; Pristauz, G; Seifert, M; Steger, G; Stoeger, H | 1 |
| Benzaïd, I; Bonnelye, E; Clézardin, P; Green, J; Mönkkönen, H; Mönkkönen, J; Stresing, V; Touraine, JL | 1 |
| Guo, A; Hatoum, HT; Lin, SJ; Lipton, A; Smith, MR | 1 |
| Frustino, JL; Kossoff, EB; Ngamphaiboon, N; O'Connor, TL; Sullivan, MA | 1 |
| Aktas, I; Atalay, B; Aybar, B; Cetin, O; Emes, Y; Issever, H; Mandel, NM; Oncu, B; Yalcin, S | 1 |
| He, W; Liu, XA; Yang, T; Zhang, PL; Zhou, WB | 1 |
| Brassard, P; Smiechowski, B; Suissa, D; Suissa, S | 1 |
| Berenson, JR | 1 |
| Jacobs, I; Lipton, A | 1 |
| Blackwell, KL; Clay, TM; Hamilton, E | 1 |
| Ahn, SG; Hwang, SH; Jeong, J; Lee, HD; Lee, HM; Lee, SA | 1 |
| Chlebowski, RT; Col, N | 2 |
| Koul, HK; Koul, S; Meacham, RB | 1 |
| Ishiguro, N; Iwase, T; Kishimoto, Y; Koyama, A; Masui, T; Matsuo, H; Yoshida, G | 1 |
| Hu, X; Jia, Z; Sun, S; Wang, B; Wang, Z; Xu, X; Zhang, J; Zhang, Q; Zhao, X | 1 |
| Curi, MM; Lascala, CA; Marques, MM; Martins, MA; Martins, MD; Migliorati, CA; Tenis, CA | 1 |
| Clézardin, P; Gnant, M | 1 |
| Argonza-Aviles, E; Beck, JT; Bosserman, L; Brufsky, AM; Ericson, SG; Harker, WG; Hohneker, J; Jin, L; Perez, EA; Seidler, C; Vogel, C; Warsi, G | 1 |
| Barrett-Lee, PJ; Bell, R; Burkinshaw, R; Cameron, D; Coleman, RE; Davies, C; Dodwell, D; Gaunt, C; Gil, M; Gregory, W; Grieve, RJ; Hiley, V; Houston, SJ; Keane, M; Marshall, H; Peterson, J; Pugh, J; Rea, U; Ritchie, D | 1 |
| Fujii, A; Fukuuchi, A; Ishizuna, K; Mori, M; Nishi, T; Ota, D; Teraoka, M | 1 |
| Deleu, I; Frassoldati, A; Jerusalem, G; Llombart, A; Mebis, J; Miller, J; Neven, P; Paija, O; Schenk, N; Sleeboom, HP | 1 |
| Henk, HJ; Kaura, S | 1 |
| Adamo, D; Aria, M; Fortuna, G; Leuci, S; Mignogna, MD; Orabona, GD; Pollio, A; Ruoppo, E | 1 |
| Du, Y; Jiang, Y; Lu, J; Shao, Z; Yan, T; Yin, W; Zhou, L; Zhou, Q | 1 |
| Andreadis, D; Epivatianos, A; Markopoulos, A; Mauroudis, S; Poulopoulos, A | 1 |
| Beuzeboc, P; Deray, G; Gligorov, J; Janus, N; Launay-Vacher, V; Le Tourneau, C; Ray-Coquard, I; Spano, JP | 1 |
| Hayashi, N; Hortobagyi, GN; Liu, J; Niikura, N; Palla, SL; Theriault, RL; Tokuda, Y; Ueno, NT | 1 |
| Choi, YK; Jeong, J; Lee, HD; Lee, KS; Oh, YJ | 1 |
| Bernstein-Molho, R; Geffen, DB; Greenberg, J; Inbar, MJ; Pelles-Avraham, S; Safra, T; Sarid, D; Stemmer, SM; Stephansky, I | 1 |
| Benad, P; Ebert, R; Hofbauer, LC; Jakob, F; Klein-Hitpass, L; Klotz, B; Meissner-Weigl, J; Rachner, TD; Rudert, M; Zeck, S | 1 |
| Eisenberg, S | 1 |
| Amodeo, V; Bazan, V; Caruso, S; Corsini, LR; Di Gaudio, F; Fanale, D; Insalaco, L; Margarese, N; Russo, A; Santini, D; Terrasi, M | 1 |
| Fukunaga, M; Horiguchi, J; Hozumi, Y; Ishikawa, T; Iwase, T; Kohno, N; Nakamura, S; Noguchi, S; Taguchi, T; Takahashi, M; Takahashi, S | 1 |
| Dank, M; Kulka, J; Langmár, Z; Szász, AM; Székely, B; Szentmártoni, G | 1 |
| Becker, S; Fehm, T; Gebauer, G; Hirnle, P; Huober, J; Janni, W; Krämer, B; Lück, HJ; Solomayer, EF; Wackwitz, B; Wallwiener, D | 1 |
| Chung, K; Cong, Z; Danese, M; Dansey, R; Halperin, M; Henry, D; Qian, Y; Rader, M; Stopeck, A | 1 |
| Bartiromo, A; Botti, G; Buonfanti, G; Colantuoni, G; D'Aiuto, M; D'Aniello, R; Daniele, G; De Feo, G; De Laurentiis, M; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Giordano, P; Gravina, A; Labonia, V; Landi, G; Lastoria, S; Maiolino, P; Morabito, A; Normanno, N; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E; Signoriello, S; Tinessa, V | 1 |
| Chen, YM; Costa, L; Hadji, P; Kosmidis, P; Lipton, A | 1 |
| Botteman, MF; Carter, JA; Kaura, S; Snedecor, SJ | 1 |
| Aft, RL; Naughton, M; Trinkaus, K; Weilbaecher, K | 1 |
| Dong, S; Du, C; Li, JS; Liu, WC; Ma, DC; Ma, YG; Wang, XJ; Wu, L; Xie, MJ; Xie, XP; Yu, ZB | 1 |
| Blumer, KJ; Chinault, SL; Kaltenbronn, KM; Penly, A; Piwnica-Worms, D; Prior, JL; Weilbaecher, KN | 1 |
| Diener, M; Namjoshi, M; Sorg, R; Wu, EQ; Xie, J | 1 |
| Freiberger, JJ; Kraft, KH; McGraw, T; Moon, RE; Padilla-Burgos, R; Piantadosi, CA; Stolp, BW; Suliman, HB | 1 |
| Abdelkarim, M; Crepin, M; Di Benedetto, M; Jais, JP; Kassis, N; Lecouvey, M; Perret, GY; Vintonenko, N | 1 |
| Coleman, R; Gnant, M; Green, J; Hadji, P | 1 |
| Clezardin, P; Coleman, R; Gnant, M; Morgan, G | 1 |
| Arao, T; Mori, H; Okada, Y; Tanaka, Y; Torimoto, K | 1 |
| Fehm, T; Neubauer, H; Seeger, H; Wallwiener, D; Zwirner, M | 1 |
| Huang, C; Huang, WW; Lin, L; Liu, J; Zheng, HY | 1 |
| Canuto, RA; Carossa, S; Maggiora, M; Martinasso, G; Mozzati, M; Muzio, G; Oraldi, M; Scoletta, M; Zambelli, M | 1 |
| Dedes, PG; Gialeli, Ch; Kanakis, I; Karamanos, NK; Kletsas, D; Theocharis, AD; Tsonis, AI; Tzanakakis, GN | 1 |
| Bell, R; Bourgeois, H; Braun, A; Brufsky, A; Chung, K; Dansey, R; Diel, I; Eniu, A; Fallowfield, L; Fan, M; Fujiwara, Y; Jassem, J; Jiang, Q; Martin, M; Paterson, AH; Ritchie, D; Steger, GG; Stopeck, A; Vogel, C | 1 |
| Body, JJ; Braun, A; Chung, K; Cleeland, CS; Clemons, M; Dansey, R; de Boer, R; Fallowfield, L; Jiang, Q; Lipton, A; Masuda, N; Mathias, SD; Oliveira, CT; Patrick, DL; Qian, Y; Salvagni, S; Stopeck, A; Tonkin, K; von Moos, R | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Lipton, A | 1 |
| Caraglia, M; Castellano, M; De Cicco, F; Leonetti, C; Misso, G; Porru, M; Santini, D; Stoppacciaro, A | 1 |
| Brufsky, AM; Oesterreich, S; Steinman, RA | 1 |
| Choksi, P; Taxel, P; Van Poznak, C | 1 |
| Hashimoto, T; Kaise, H; Kohno, N; Koizumi, K; Okamoto, J; Tokuuye, K; Uchida, K; Yamada, K; Yoshimura, M | 1 |
| Houts, AC; Miller, PJ; Namjoshi, M; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Barrios, C; Bundred, N; Campbell, I; Coleman, R; Davidson, N; de Boer, R; Eidtmann, H; Forbes, J; Frassoldati, A; Llombart, A; Martin, N; Modi, A; Neven, P; Paija, O; Sleeboom, HP; von Minckwitz, G | 1 |
| Barney, RB; Biskupiak, JE; Brandt, P; Gaffney, DK; Namjoshi, M; Nickman, NA; Young, J | 1 |
| Iwasaki, M; Li, W; Minato, N; Morita, CT; Murata-Hirai, K; Okamura, H; Sugie, T; Tanaka, Y; Toi, M | 1 |
| Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB | 1 |
| Body, JJ; Brown, J; Coleman, R; Cook, R; Lipton, A; Smith, M | 1 |
| Collins, LI; Davis, JL; Faccio, R; Mach, RH; Novack, DV; Piwnica-Worms, D; Su, X; Vangveravong, S; Vora, P; Weilbaecher, KN; Yang, C; Zeng, R | 1 |
| Bastit, L; El Kouri, C; Guérif, S; Ktiouet, M; Lebret, T; Lortholary, A; Mouysset, JL; Murraciole, X; Slimane, K | 1 |
| Garrett, Z; Jilani, A; Stevens, A; Sutcliffe, F | 1 |
| Edwards, S; Laing, K; McCarthy, J; McCrate, F; Murphy, L; Powell, E; Seal, M | 1 |
| Dedes, PG; Gialeli, Ch; Kanakis, I; Karamanos, NK; Kletsas, D; Theocharis, AD; Tsegenidis, T; Tzanakakis, GN | 1 |
| Hortobagyi, GN | 1 |
| Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M | 1 |
| Lipton, A | 4 |
| Cook, R; Major, PP | 1 |
| Harland, SJ; Oosterlinck, W; Rosen, L | 1 |
| Denoyelle, C; Hong, L; Soria, C; Soria, J; Vannier, JP | 1 |
| Booth, B; Chen, G; Gobburu, JV; Hsieh, Y; Ibrahim, A; Leighton, J; Li, N; Pazdur, R; Rahman, A; Scher, N; Sridhara, R; Vause, D; Williams, G; Wood, R | 1 |
| Crispino, J; Fraterrigo, T; Green, J; Lipton, A; Witters, LM | 1 |
| Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ | 1 |
| Hohneker, J; Lacerna, L | 1 |
| Cameron, D | 1 |
| Coleman, R; Croucher, P; Jagdev, S | 1 |
| Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J | 1 |
| Castel, LD; Glendenning, GA; Li, Y; Schulman, KA; Timbie, JW; Weinfurt, KP | 1 |
| Bartsch, R; Hussian, D; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Hershman, D; Narayanan, R | 1 |
| Aglietta, M; Cirillo, S; Gatti, M; Martincich, L; Montemurro, F; Regge, D; Russo, F | 1 |
| Hiraga, T; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T | 1 |
| Andreadis, C; Charalampidou, M; Chouchos, N; Diamantopoulos, N; Mouratidou, D | 1 |
| Coleman, RE; Evans, CA; Holen, I; Neville-Webbe, HL; Rostami-Hodjegan, A | 1 |
| Bielawski, KP; Bosse, U; Schlotter, CM; Vogt, U | 1 |
| Bria, E; Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Meloni, G; Papaldo, P; Petti, MC; Picardi, A; Zeuli, M | 1 |
| Decker, JL; Henderson, C; Hohneker, JA; Kaplan, BH; Lacerna, L; Orlowski, R; Purdy, MH; Schnell, FM; Vogel, CL; Wood, AJ; Yanagihara, RH | 1 |
| Inoue, K; Kawada, K; Minami, H; Okabe, K; Sasaki, T; Sawamura, M; Takashima, S; Watanabe, T; Yagi, Y | 1 |
| Coleman, RE; Glendenning, GA; Radeva, JI; Reed, SD; Schulman, KA | 1 |
| Harvey, HA | 1 |
| Aogi, K; Asaga, T; Goessl, C; Iino, Y; Kohno, N; Minami, H; Nakamura, S; Ohashi, Y; Takashima, S; Watanabe, T | 1 |
| Battistoni, F; Dicuonzo, G; Gasparro, S; Gavasci, M; Grilli, C; La Cesa, A; Rocci, L; Santini, D; Tonini, G; Vincenzi, B; Virzì, V | 1 |
| Gralow, J | 1 |
| Barrett-Lee, P; Cameron, D; Davidson, N; Dodwell, D; Hong, A; Mansi, J; Mason, T; Murphy, R; Wardley, A | 1 |
| Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP | 2 |
| Nelson, MV | 1 |
| Schwartz, JE | 1 |
| Clegg, JP; Davie, AM; Guest, JF; McCloskey, E | 1 |
| Crowley, J; Durie, BG; Katz, M | 1 |
| Gordon, DH | 1 |
| Duck, L; Maerevoet, M; Martin, C | 1 |
| Dunleavy, R; Liauw, W; Lih, A; Links, M; Segelov, E; Ward, R | 1 |
| Alimonti, A; Bordignon, V; Carlini, P; Cognetti, F; Cordiali Fei, P; D'Agosto, G; Di Cocco, B; Di Cosimo, S; Fabi, A; Ferretti, G; Giannarelli, D; Papaldo, P; Salesi, N; Trento, E | 1 |
| Coleman, RE; Holen, I; Neville-Webbe, HL; Woodward, JK | 1 |
| Barutca, S; Erdogan, S; Koseoglu, K; Meydan, N; Yurekli, Y | 1 |
| Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M | 1 |
| Broumand, V; Fortin, M; Marx, RE; Sawatari, Y | 1 |
| Fietkau, R; Gundlach, KK; Lenz, JH; Mueller, PC; Schmidt, W; Steiner-Krammer, B | 1 |
| Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Melisi, D; Tortora, G; Veneziani, BM | 1 |
| Bleik, JH; El Saghir, NS; Otrock, ZK | 1 |
| Aguirre, A; Campbell, JH; Margarone, JE; Markiewicz, MR | 1 |
| Etayo-Pérez, A; Garatea-Crelgo, J; Martino-Gorbea, R; Pastor-Zuazaga, D; Sebastián-López, C | 1 |
| Klain, M; Liuzzi, R; Marinelli, A; Molino, L; Pace, L; Paone, G; Salvatore, M; Soricelli, A; Storto, G | 1 |
| Inoue, K; Iwase, H; Kawazoe, T; Nagamoto, N; Nakahara, O; Ohsako, T; Sakamoto, N; Yamamoto, Y; Yoshida, Y | 1 |
| Aapro, M | 1 |
| Aglietta, M; Faggiuolo, R; Goia, F; Montemurro, F; Nanni, D; Ortega, C; Vormola, R | 1 |
| Coleman, RE; Evans, CA; Holen, I; Neville-Webbe, HL | 1 |
| Soileau, KM | 1 |
| Franke, HR; Verdijk, R; Vermes, I; Wolbers, F | 1 |
| Budman, DR; Calabro, A | 1 |
| Brufsky, A | 1 |
| Chen, NL; Diaz-Borjon, A; Lim, SS; Seyler, TM | 1 |
| Avcu, F; Candir, M; Guden, M; Ozcan, MA; Ural, AU | 1 |
| Baumann, A; Czerny, C; Eisenmenger, G; Ewers, R; Hoffmann, M; Moser, D; Pietschmann, P; Wutzl, A | 1 |
| Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G | 1 |
| Caraglia, M; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Furlow, B | 1 |
| Barnett, JB; de Lemos, ML; Hu, F; Levin, A; Moravan, V; O'Reilly, SE; Taylor, SC | 1 |
| Beck, JT; Brufsky, A; Carroll, R; Harker, WG; Hohneker, J; Lacerna, L; Perez, EA; Petrone, S; Seidler, C; Tan-Chiu, E | 1 |
| Galid, A; Gnant, MF; Grampp, S; Hausmaninger, H; Jakesz, R; Kaessmann, H; Luschin-Ebengreuth, G; Menzel, C; Mittlboeck, M; Mlineritsch, B; Piswanger-Soelkner, JC; Schmid, M | 1 |
| Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E | 1 |
| Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U; Cabrera Suárez, MA; Quintero Pérez, S | 1 |
| Iguchi, H | 1 |
| Araújo, SR; Cossolin, GS; Curi, MM; dos Santos, MO; Feher, O; Koga, DH; Zardetto, C | 1 |
| Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M | 1 |
| Brunelli, C; Campa, T; De Conno, F; Fagnoni, E; Giardina, V; Pigni, A; Ripamonti, C | 1 |
| Cook, RJ; Lee, KA; Li, H | 1 |
| Duivenvoorden, WC; Kalina, M; Seidlitz, E; Singh, G; Vukmirović-Popović, S | 1 |
| Bergström, B; Body, JJ; Garnero, P; Lichinitser, M; Tjulandin, S | 1 |
| Fantini, M; Nicoletti, S; Poggi, B; Possenti, C; Sartori, S; Tamburini, E; Tassinari, D | 1 |
| Ahmad, K | 1 |
| Avcu, F; Baran, Y; Ural, AU | 1 |
| Barrett-Lee, P; Bloomfield, D; Dougherty, L; Harries, M; Laing, R; Patel, H; Walker, M | 1 |
| Gralow, JR | 1 |
| Bäuerle, T; Berger, MR; Peterschmitt, J | 1 |
| Briones, DL; Ferres, AJ; Herbozo, PJ; Torrealba, RL | 1 |
| Berman, AW; Brahim, JS; Denduluri, N; Goldman, ML; Guadagnini, JP; Kleiner, DE; Sausville, R; Swain, SM | 1 |
| Crescimanno, M; Flandina, C; Leto, G; Tumminello, FM | 1 |
| Bellomi, M; Bruschini, R; Cossu Rocca, M; Goldhirsch, A; Nole, F; Preda, L; Sanna, G; Verri, E | 1 |
| Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR | 1 |
| Engroff, SL; Kim, DD | 1 |
| Budillon, A; Caraglia, M; Facchini, G; Fiore, F; Iaffaioli, RV; Maiolino, P; Nasti, G; Ottaiano, A; Ruberto, M; Santini, D; Striano, S; Tonini, G; Zeppetella, GL | 1 |
| Bundred, N; Hadji, P | 1 |
| Kohno, N; Yamada, K | 1 |
| Body, JJ; Chaboteaux, C; Duvillier, H; Journé, F; Kheddoumi, N; Laurent, G | 1 |
| Aksoy, S; Altundag, K; Cengiz, M; Dincer, M; Gullu, I; Harputluoglu, H | 1 |
| Camlica, H; Duranyildiz, D; Oguz, H; Tas, F; Topuz, E; Yasasever, V | 1 |
| Bundred, NJ; Campbell, ID; Coleman, RE; Davidson, N; DeBoer, RH; Eidtmann, H; Miller, JC; Monnier, A; Neven, P; Schenk, NL; von Minckwitz, G | 1 |
| Friese, K; Janni, W; Rack, B; Schindlbeck, C; Sommer, H; Strobl, B | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R | 1 |
| Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A | 1 |
| McKeage, K; Plosker, GL | 1 |
| Dhillon, S; Lyseng-Williamson, KA | 1 |
| Beith, JM; Moore, MM | 1 |
| Baldini, E; Barni, S; Berto, P; Cortesi, E; Dauria, G; Schivazappa, C | 1 |
| Badia, X; Chow, E; Costa, L; Lipton, A; Wardley, A | 1 |
| Moore, S; Reilly, MM | 1 |
| Agrati, C; Fratto, ME; Galluzzo, S; Manavalan, JS; Martini, F; Piacentini, P; Poccia, F; Rocci, L; Santini, D; Tonini, G; Turchi, F; Vincenzi, B | 1 |
| Badalamenti, G; D'Amico, C; Fulfaro, F; Incorvaia, L; Leto, G; Tumminello, FM | 1 |
| Aguggini, S; Allevi, G; Angeli, A; Berruti, A; Bonardi, S; Bottini, A; Dogliotti, L; Dovio, A; Generali, D; Harris, AL; Milani, M; Tampellini, M; Tedoldi, S; Torta, M; Tucci, M | 1 |
| Braidman, IP; Evans, CE | 1 |
| Ziegler, J | 1 |
| Enomoto, K | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Arnett, TR; Colston, KW; Mansi, JL; Pirianov, G; Senaratne, SG | 1 |
| Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
| Body, JJ; Fromigue, O; Lagneaux, L | 1 |
| Berenson, JR; Coleman, RE; Dreicer, R; Howell, A; Kuross, SA; Lipton, A; Morley, W; Porter, L; Rosen, LS; Seaman, JJ | 1 |
| Coleman, RE; Croucher, PI; Jagdev, SP; Rostami-H, A; Shipman, CM | 1 |
| Ali, SM; Costa, L; Esteva, FJ; Harvey, H; Hortobagyi, G; Knight, R; Lipton, A; Seaman, J | 1 |
| Clézardin, P; Delmas, P; Pécheur, I; Peyruchaud, O; Serre, CM; Winding, B | 1 |
| Mykała-Cieśla, J; Stajszczyk, M | 1 |
| Colston, KW; Mansi, JL; Senaratne, SG | 1 |
| Getz, B; Ingle, JN; Karpeisky, MY; Mikhailov, SN; Padyukova, NSh; Reinholz, GG; Sanders, ES; Spelsberg, TC | 1 |
107 review(s) available for zoledronic acid and Breast Cancer
| Article | Year |
|---|---|
Role of syndecan-4 in breast cancer pathophysiology.
Topics: Breast Neoplasms; Estrogens; Extracellular Matrix Proteins; Female; Heparan Sulfate Proteoglycans; Humans; Integrins; Intercellular Signaling Peptides and Proteins; Ligands; MicroRNAs; Progesterone; Receptors, Estrogen; Syndecan-1; Syndecan-4; Trastuzumab; Tumor Microenvironment; Zoledronic Acid | 2022 |
The effects of neoadjuvant zoledronic acid in breast cancer patients: A meta-analysis of randomized controlled trials.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Zoledronic Acid | 2023 |
Differences between zoledronic acid and denosumab for breast cancer treatment.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Denosumab; Female; Humans; Imidazoles; Zoledronic Acid | 2023 |
Bisphosphonates and breast cancer - From cautious palliation to saving lives.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Quality of Life; Tumor Microenvironment; Zoledronic Acid | 2020 |
[Gastrointestinal symptoms revealing COVID-19 in Malian breast cancer patient undergoing chemotherapy].
Topics: Adult; Antineoplastic Agents, Phytogenic; Betacoronavirus; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Coronavirus Infections; COVID-19; Diarrhea; Docetaxel; Fatal Outcome; Female; HIV Infections; Humans; Liver Neoplasms; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spinal Neoplasms; Tomography, X-Ray Computed; Vomiting; Zoledronic Acid | 2020 |
"The use of bisphosphonates to treat skeletal complications in solid tumours".
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Male; Quality of Life; Zoledronic Acid | 2021 |
Bone-modifying Agents (BMAs) in Breast Cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid | 2021 |
The Roadmap of RANKL/RANK Pathway in Cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Denosumab; Drug Repositioning; Female; Humans; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Zoledronic Acid | 2021 |
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2017 |
Therapeutic approaches for protecting bone health in patients with breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Denosumab; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Practice Guidelines as Topic; Spinal Cord Compression; Zoledronic Acid | 2018 |
Bisphosphonates and other bone agents for breast cancer.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
Parotid gland metastasis from carcinoma of the breast detected by PET/CT: Case report and review.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Mastectomy, Segmental; Parotid Gland; Parotid Neoplasms; Positron Emission Tomography Computed Tomography; Zoledronic Acid | 2018 |
Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: A network meta-analysis.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Network Meta-Analysis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Zoledronic Acid | 2019 |
Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Zoledronic Acid | 2019 |
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Female; Humans; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2019 |
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Fractures, Bone; Humans; Imidazoles; Neoplasm Staging; Osteoporosis; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2013 |
Zoledronic acid in the treatment of metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Patient Compliance; Quality of Life; Zoledronic Acid | 2014 |
[Inhibition of RANK ligand to treat bone metastases].
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2013 |
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Neoplasm Metastasis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2013 |
Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2013 |
Bisphosphonate-related atypical femoral fracture with bone metastasis of breast cancer: case report and review.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Femoral Fractures; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Prognosis; Zoledronic Acid | 2014 |
Atraumatic tooth extraction in patients taking bisphosphonates: a review of literature and experience with three cases.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Elastomers; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Orthodontic Appliances; Pancoast Syndrome; Prostatic Neoplasms; Retrospective Studies; Tooth Extraction; Zoledronic Acid | 2014 |
Routine use of zoledronic acid in early-stage breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Neoplastic Cells, Circulating; Randomized Controlled Trials as Topic; Zoledronic Acid | 2015 |
Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid.
Topics: Arm; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Buttocks; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Diphosphonates; Drug Eruptions; Erythema; Female; Humans; Imidazoles; Intertrigo; Lung Neoplasms; Middle Aged; Mixed Tumor, Malignant; Syndrome; Zoledronic Acid | 2015 |
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Consensus; Diphosphonates; Europe; Female; Humans; Imidazoles; Neoplasm Recurrence, Local; Osteoporosis; Surveys and Questionnaires; Zoledronic Acid | 2016 |
Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Postmenopause; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome; Zoledronic Acid | 2016 |
Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Postmenopause; Randomized Controlled Trials as Topic; Time Factors; Zoledronic Acid | 2016 |
Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Orthopedic Procedures; Prostatic Neoplasms; Radiotherapy; Spinal Cord Compression; Zoledronic Acid | 2017 |
Osteoporosis management in patients with breast cancer: EMAS position statement.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Neoplasm Recurrence, Local; Osteoporosis; Premenopause; Zoledronic Acid | 2017 |
Zoledronic acid: a review of its use in breast cancer.
Topics: Antineoplastic Agents; Area Under Curve; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Injections, Intravenous; Zoledronic Acid | 2008 |
Medical oncology: zoledronic acid prevents bone loss in early-stage breast cancer.
Topics: Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Survival Analysis; Treatment Outcome; Women's Health; Zoledronic Acid | 2009 |
Bisphosphonates in breast cancer: teaching an old dog new tricks.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Treatment Outcome; Zoledronic Acid | 2009 |
Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2009 |
Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Male; Mice; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic; Zoledronic Acid | 2010 |
[New development in breast cancer therapy. III. Zoledronic acid and anti-tumor immunity in breast cancer].
Topics: Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Zoledronic Acid | 2009 |
Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Marrow Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2010 |
The anti-tumor effect of bisphosphonates ABCSG-12, ZO-FAST and more ...
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Zoledronic Acid | 2010 |
The evolving role of bone-conserving therapy in patients with breast cancer.
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Survival Analysis; Zoledronic Acid | 2010 |
Future directions of bone-targeted therapy for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cathepsin K; Chemoreceptor Cells; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Ligands; NF-kappa B; Parathyroid Hormone; RANK Ligand; src-Family Kinases; Transforming Growth Factor beta; Zoledronic Acid | 2010 |
Dosing of zoledronic acid throughout the treatment continuum in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Injections, Intravenous; Neoplasm Staging; Osteoporosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome; Zoledronic Acid | 2011 |
[Bisphosphonates in adjuvant therapy of breast cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Controlled Clinical Trials as Topic; Diphosphonates; Drug Approval; Estrogen Antagonists; Evidence-Based Medicine; Female; Humans; Imidazoles; Neoplasm Staging; Osteoporosis; Pamidronate; Survival Rate; Zoledronic Acid | 2010 |
Bisphosphonates as anticancer therapy for early breast cancer.
Topics: Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Cell Proliferation; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Neovascularization, Physiologic; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2010 |
The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Zoledronic Acid | 2010 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
Managing bone health with zoledronic acid: a review of randomized clinical study results.
Topics: Antineoplastic Agents; Bone and Bones; Bone Demineralization, Pathologic; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Drug Monitoring; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Postmenopause; Randomized Controlled Trials as Topic; Zoledronic Acid | 2011 |
Zoledronic acid use in cancer patients: more than just supportive care?
Topics: Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Neoplasms; Osteolysis; Zoledronic Acid | 2011 |
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Mice; Multiple Myeloma; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2011 |
Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Breast Neoplasms; Clodronic Acid; Diphosphonates; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Treatment Outcome; Zoledronic Acid | 2011 |
[Encounter of cancer cells with bone. Treatment of bone metastases from breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Molecular Targeted Therapy; Osteoclasts; Pamidronate; RANK Ligand; Strontium; Zoledronic Acid | 2011 |
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Zoledronic Acid | 2011 |
New developments for treatment and prevention of bone metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Neoplasm Recurrence, Local; Osteonecrosis; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2011 |
Pharmacokinetic evaluation of zoledronic acid.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Drug Evaluation; Female; Humans; Imidazoles; Osteoporosis; Zoledronic Acid | 2011 |
Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis.
Topics: Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Musculoskeletal Diseases; Randomized Controlled Trials as Topic; Zoledronic Acid | 2011 |
Antitumor effects of bisphosphonates: from the laboratory to the clinic.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Cell Adhesion Molecules; Diphosphonates; Female; Humans; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2011 |
Denosumab: benefits of RANK ligand inhibition in cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Multiple Myeloma; RANK Ligand; Zoledronic Acid | 2011 |
New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lymphocyte Activation; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2011 |
Bisphosphonates and breast cancer prevention.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2012 |
Anticancer activity of bisphosphonates in breast cancer.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2012 |
New role for an established drug? Bisphosphonates as potential anticancer agents.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Clinical Trials as Topic; Diphosphonates; Drug Synergism; Female; Humans; Imidazoles; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Osteoclasts; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid | 2012 |
Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease-Free Survival; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Male; Osteoclasts; Prostatic Neoplasms; Tumor Microenvironment; Zoledronic Acid | 2012 |
The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Survival Analysis; Zoledronic Acid | 2012 |
Zoledronic acid in the treatment of early-stage breast cancer: is there a final verdict?
Topics: Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Survival Rate; Zoledronic Acid | 2012 |
Bisphosphonates and breast cancer incidence and recurrence.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Incidence; Zoledronic Acid | 2011 |
Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis; Treatment Outcome; Zoledronic Acid | 2011 |
Primary systemic therapy in breast cancer--an update for gynecologic oncologists.
Topics: Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Neoadjuvant Therapy; Zoledronic Acid | 2011 |
The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis.
Topics: Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Marrow; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Menopause; Neoplasm Metastasis; Zoledronic Acid | 2012 |
Effects of bone-targeted agents on cancer progression and mortality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Disease Progression; Disease-Free Survival; Female; Goserelin; Humans; Imidazoles; Male; Menopause; Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome; Zoledronic Acid | 2012 |
Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Neoplasm Metastasis; Prostatic Neoplasms; Women's Health; Zoledronic Acid | 2012 |
Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Humans; Imidazoles; Recurrence; Treatment Outcome; Zoledronic Acid | 2012 |
Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Breast Neoplasms; Cell Movement; Diphosphonates; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Imidazoles; Immunity; Intercellular Signaling Peptides and Proteins; Neovascularization, Pathologic; Signal Transduction; Tumor Microenvironment; Zoledronic Acid | 2012 |
The management of osteoporosis in breast cancer survivors.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Zoledronic Acid | 2012 |
Bisphosphonates in the adjuvant treatment of breast cancer.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2013 |
Novel approaches to the management of bone metastases in patients with breast cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2002 |
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Osteoporosis; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Safety; Zoledronic Acid | 2002 |
Bisphosphonates and metastatic breast carcinoma.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Forecasting; Glycoproteins; Humans; Imidazoles; Infusions, Intravenous; Osteoprotegerin; Pamidronate; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Zoledronic Acid | 2003 |
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Male; Models, Statistical; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2002 |
Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid | 2002 |
Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid | 2003 |
Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2003 |
Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Osteolysis; Prognosis; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; United Kingdom; Zoledronic Acid | 2003 |
The anti-tumor potential of zoledronic acid.
Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Male; Mice; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Zoledronic Acid | 2003 |
Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Infusions, Intravenous; Osteoblasts; Osteolysis; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2003 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Quality of Life; Risedronic Acid; Risk Factors; Treatment Outcome; Vitamin D; Zoledronic Acid | 2004 |
Management of bone metastases in breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Middle Aged; Palliative Care; Pamidronate; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2005 |
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Pamidronate; Postmenopause; Triazoles; Zoledronic Acid | 2004 |
Bisphosphonates in breast cancer.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Staging; Pamidronate; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2005 |
Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Osteonecrosis; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; United States; Women's Health; Zoledronic Acid | 2005 |
New therapeutic agents for the treatment of bone diseases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Triazoles; Zoledronic Acid | 2006 |
Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Premenopause; Randomized Controlled Trials as Topic; Zoledronic Acid | 2006 |
[Molecular mechanism and potential targets for bone metastasis].
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Mice; Mice, Nude; Neoplastic Cells, Circulating; Osteolysis; Parathyroid Hormone-Related Protein; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2007 |
Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Practice Guidelines as Topic; Treatment Outcome; Zoledronic Acid | 2007 |
On the horizon: can bisphosphonates prevent bone metastases?
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Evidence-Based Medicine; Female; Humans; Imidazoles; Models, Animal; Neoplasm Staging; Treatment Outcome; Zoledronic Acid | 2007 |
Reducing the risk of bone loss associated with breast cancer treatment.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Risk Factors; Women's Health; Zoledronic Acid | 2007 |
Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Neoplasm Staging; Osteoporosis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2007 |
Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Risk Factors; Zoledronic Acid | 2007 |
[Clinical study of bisphosphonates for bone metastasis in breast cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Osteoclasts; Pain; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; Zoledronic Acid | 2007 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid | 2008 |
Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Neoplasm Staging; Neoplasms, Hormone-Dependent; Premenopause; Randomized Controlled Trials as Topic; Zoledronic Acid | 2007 |
Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Zoledronic Acid | 2008 |
Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2008 |
Impact of skeletal complications on patients' quality of life, mobility, and functional independence.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Health Status; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Quality of Life; Zoledronic Acid | 2008 |
[New drugs in metastatic breast cancer--1997].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Diphosphonates; Drug Resistance, Multiple; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Tamoxifen; Taxoids; Triazoles; Zoledronic Acid | 1997 |
Clinical research update: zoledronate.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Mice; Multiple Myeloma; Rats; Zoledronic Acid | 1997 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
[Bisphosphonates in the treatment of breast carcinoma].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; Zoledronic Acid | 2001 |
128 trial(s) available for zoledronic acid and Breast Cancer
| Article | Year |
|---|---|
Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Pain; Quality of Life; Zoledronic Acid | 2022 |
Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Zoledronic Acid | 2022 |
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.
Topics: Adjuvants, Immunologic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Treatment Outcome; Zoledronic Acid | 2023 |
Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women.
Topics: Aged; Bone Density; Bone Diseases, Metabolic; Breast Neoplasms; Double-Blind Method; Female; Heart Neoplasms; Humans; Zoledronic Acid | 2020 |
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Disease-Free Survival; Female; Fractures, Spontaneous; Humans; Middle Aged; Risk Assessment; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2020 |
Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Imidazoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Treatment Outcome; Zoledronic Acid | 2021 |
Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Intercellular Signaling Peptides and Proteins; Leukocyte Count; Male; Middle Aged; Osteolysis; Platelet Count; Platelet-Rich Fibrin; Prostatic Neoplasms; Young Adult; Zoledronic Acid | 2021 |
Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
Topics: Bone Density Conservation Agents; Bone Diseases; Breast Neoplasms; Cost-Benefit Analysis; Czech Republic; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Markov Chains; Models, Econometric; Neoplasms; Prostatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; Zoledronic Acid | 2017 |
Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Markov Chains; Zoledronic Acid | 2017 |
Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Kaplan-Meier Estimate; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Proto-Oncogene Proteins c-maf; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2017 |
Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diphosphonates; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Imidazoles; Mastectomy, Segmental; Neoadjuvant Therapy; Paclitaxel; Postmenopause; Receptor, ErbB-2; Zoledronic Acid | 2017 |
Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Intraepithelial Lymphocytes; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome; Triazoles; Zoledronic Acid | 2018 |
Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
Topics: Biomarkers, Tumor; Bone and Bones; Bone Development; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Early Detection of Cancer; Female; Humans; Infusions, Intravenous; Middle Aged; Prognosis; Standard of Care; United Kingdom; Zoledronic Acid | 2018 |
Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study.
Topics: Adult; Aged; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Zoledronic Acid | 2018 |
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Middle Aged; Musculoskeletal Diseases; Odds Ratio; Proportional Hazards Models; Treatment Outcome; Zoledronic Acid | 2018 |
Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial.
Topics: Administration, Intravenous; Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Middle Aged; Premenopause; Prospective Studies; Time Factors; Treatment Outcome; Young Adult; Zoledronic Acid | 2018 |
Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteoblasts; Palliative Care; Prostatic Neoplasms; Quality of Life; Radiopharmaceuticals; Safety; Survival Analysis; Zoledronic Acid | 2018 |
Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Young Adult; Zoledronic Acid | 2018 |
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Estrogen Antagonists; Female; Humans; Italy; Letrozole; Middle Aged; Ovary; Premenopause; Tamoxifen; Time Factors; Triptorelin Pamoate; Zoledronic Acid | 2019 |
Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
Topics: Age Factors; Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Peptides; Radionuclide Imaging; Zoledronic Acid | 2013 |
Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follistatin; Humans; Imidazoles; Inhibins; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Receptor, ErbB-2; Receptors, Estrogen; Taxoids; Time Factors; Transforming Growth Factor beta1; Treatment Outcome; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate; Time Factors; Zoledronic Acid | 2013 |
RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Middle Aged; Osteoprotegerin; Peptides; Prospective Studies; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Zoledronic Acid | 2013 |
Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer.
Topics: Adult; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Prevalence; Zoledronic Acid | 2014 |
Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Middle Aged; Oral Health; Osteonecrosis; Quality of Life; Zoledronic Acid | 2013 |
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Pain; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Young Adult; Zoledronic Acid | 2013 |
QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Comprehension; Diphosphonates; England; Female; Health Knowledge, Attitudes, Practice; Health Services Accessibility; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Pain Measurement; Patient Preference; Patient Satisfaction; Patients; Qualitative Research; Quality of Life; Time Factors; Treatment Outcome; Wales; Zoledronic Acid | 2013 |
Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Marrow; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Time Factors; Tumor Burden; Zoledronic Acid | 2013 |
Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
Topics: Adult; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Radioimmunoassay; Zoledronic Acid | 2014 |
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Zoledronic Acid | 2014 |
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy".
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Immunohistochemistry; Middle Aged; Neoplastic Cells, Circulating; Zoledronic Acid | 2014 |
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Prospective Studies; Triazoles; Zoledronic Acid | 2014 |
Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Topics: Adult; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Double-Blind Method; Female; Femur; Humans; Imidazoles; Lumbar Vertebrae; Middle Aged; Osteoporosis; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Young Adult; Zoledronic Acid | 2014 |
Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Double-Blind Method; Female; Goserelin; Hormones; Humans; Imidazoles; Middle Aged; Premenopause; Prospective Studies; Tamoxifen; Young Adult; Zoledronic Acid | 2014 |
Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Doxorubicin; Female; Humans; Imidazoles; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Receptor, ErbB-2; Taxoids; Treatment Outcome; Zoledronic Acid | 2014 |
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Diphosphonates; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Detection of Cancer; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; International Cooperation; Kaplan-Meier Estimate; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2014 |
Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; Incidence; Infusions, Intravenous; Middle Aged; Odds Ratio; Postmenopause; Risk; Zoledronic Acid | 2014 |
Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Doxorubicin; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; ROC Curve; Taxoids; Treatment Outcome; Tumor Burden; Zoledronic Acid | 2014 |
Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
Topics: Absorptiometry, Photon; Adult; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Double-Blind Method; Female; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Osteoporosis; Premenopause; Zoledronic Acid | 2015 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2015 |
Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Protocols; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Postmenopause; Preoperative Care; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Triazoles; Zoledronic Acid | 2014 |
Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance).
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Double-Blind Method; Endpoint Determination; Female; Femur Neck; Humans; Imidazoles; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Reproducibility of Results; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2015 |
Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases.
Topics: Acute Disease; Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Kidney; Middle Aged; Prospective Studies; Zoledronic Acid | 2015 |
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Topics: Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Male; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2015 |
The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
Topics: Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasms; Proportional Hazards Models; Zoledronic Acid | 2015 |
Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.
Topics: Administration, Cutaneous; Aged; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Long-Term Care; Male; Middle Aged; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2016 |
Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diphosphonates; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Genes, erbB-2; Humans; Imidazoles; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Triple Negative Breast Neoplasms; Zoledronic Acid | 2015 |
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Middle Aged; Palliative Care; Pamidronate; Quality of Life; Treatment Outcome; Zoledronic Acid | 2016 |
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast; Breast Neoplasms; Dasatinib; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Receptor, ErbB-2; src-Family Kinases; Zoledronic Acid | 2016 |
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Middle Aged; Neoplasm, Residual; Zoledronic Acid | 2016 |
Bone loss after oophorectomy among high-risk women: an NRG oncology/gynecologic oncology group study.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Ovarian Neoplasms; Ovariectomy; Premenopause; Risk Factors; Zoledronic Acid | 2016 |
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Prostatic Neoplasms; Sample Size; Spinal Cord Compression; Spinal Fractures; Zoledronic Acid | 2017 |
Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Imidazoles; Middle Aged; Treatment Outcome; Zoledronic Acid | 2017 |
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Triazoles; Zoledronic Acid | 2008 |
Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.
Topics: Adult; Antineoplastic Agents; Biomarkers; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Osteoporosis; Premenopause; Zoledronic Acid | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Linear Models; Nitriles; Osteoporosis; Premenopause; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2008 |
[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
Topics: Adult; Aged; Analgesics; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Colorectal Neoplasms; Creatinine; Diphosphonates; Double-Blind Method; Female; Fever; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Pain, Intractable; Pamidronate; Peptides; Prospective Studies; Vomiting; Zoledronic Acid | 2008 |
[Clinical analysis of therapeutic effect of zoledronic acid combined with radiotherapy for metastatic bone cancer].
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Bone Regeneration; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Pain; Pain Management; Radiotherapy; Zoledronic Acid | 2008 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Estrogen Antagonists; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Premenopause; Receptors, Estrogen; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Dehydroepiandrosterone Sulfate; Diphosphonates; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hydrocortisone; Imidazoles; Letrozole; Luteinizing Hormone; Middle Aged; Nitriles; Postmenopause; Progesterone; Receptors, Estrogen; Tamoxifen; Testosterone; Triazoles; Zoledronic Acid | 2009 |
Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2009 |
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Prognosis; Survival Rate; Treatment Outcome; Triazoles; Zoledronic Acid | 2009 |
Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Pain Measurement; Palliative Care; Radiotherapy Dosage; Zoledronic Acid | 2010 |
Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imatinib Mesylate; Imidazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Piperazines; Prognosis; Prostatic Neoplasms; Pyrimidines; Sarcoma; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Premenopause; Zoledronic Acid | 2010 |
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Risk Factors; Treatment Outcome; Triazoles; Zoledronic Acid | 2010 |
Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw Diseases; Middle Aged; Osteonecrosis; Radionuclide Imaging; Radiopharmaceuticals; Technetium Tc 99m Medronate; Zoledronic Acid | 2010 |
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm, Residual; Zoledronic Acid | 2010 |
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Zoledronic Acid | 2010 |
Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Letrozole; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Survival Rate; Time Factors; Treatment Outcome; Triazoles; Zoledronic Acid | 2010 |
In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Topics: Adjuvants, Immunologic; Aged; Breast Neoplasms; Cell Proliferation; Chemokines; Cytokines; Diphosphonates; Disease Progression; Esterases; Female; Hemiterpenes; Humans; Imidazoles; Immunotherapy; Interferon-gamma; Interleukin-2; Leukocyte Common Antigens; Lymphocyte Activation; Lymphocyte Count; Lysine; Middle Aged; Mucin-1; Organophosphorus Compounds; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Salvage Therapy; T-Lymphocyte Subsets; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Tumor Necrosis Factor Receptor Superfamily, Member 7; Zoledronic Acid | 2010 |
Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Cells; Breast Neoplasms; Cell Cycle; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Middle Aged; Models, Statistical; Recurrence; Zoledronic Acid | 2010 |
Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; China; Collagen Type I; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Mucin-1; Peptides; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2010 |
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
Topics: Absorptiometry, Photon; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Femur Neck; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Osteoporosis; Premenopause; Prospective Studies; Republic of Korea; Time Factors; Treatment Outcome; Zoledronic Acid | 2011 |
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; RANK Ligand; Zoledronic Acid | 2010 |
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
Topics: Adult; Biomarkers; Biphenyl Compounds; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cathepsin K; Collagen Type I; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Treatment Outcome; Zoledronic Acid | 2010 |
Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcaneus; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Femur Neck; Follow-Up Studies; Humans; Imidazoles; Lumbar Vertebrae; Middle Aged; Neoplasm Staging; Postmenopause; Risk Factors; Survival Analysis; Tamoxifen; Treatment Outcome; Zoledronic Acid | 2010 |
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.
Topics: Adult; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Fatigue; Female; Fever; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Pain; Premenopause; Primary Ovarian Insufficiency; Prospective Studies; Zoledronic Acid | 2011 |
Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Osteonecrosis; Treatment Outcome; Zoledronic Acid | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Nitriles; Premenopause; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid | 2011 |
Bisphosphonate-related osteonecrosis: laser-assisted surgical treatment or conventional surgery?
Topics: Adult; Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Lasers, Solid-State; Low-Level Light Therapy; Lung Neoplasms; Male; Middle Aged; Peptides; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid | 2011 |
Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Topics: Adult; Aged; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Korea; Middle Aged; Osteoporosis; Postmenopause; Zoledronic Acid | 2011 |
Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
Topics: Administration, Metronomic; Adult; Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Young Adult; Zoledronic Acid | 2011 |
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Organ Size; Osteoporosis, Postmenopausal; Postmenopause; Triazoles; Zoledronic Acid | 2012 |
Breast-cancer adjuvant therapy with zoledronic acid.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Osteonecrosis; Zoledronic Acid | 2011 |
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Receptors, Estrogen; Treatment Outcome; Triazoles; Zoledronic Acid | 2012 |
Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome.
Topics: Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Forecasting; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Pain Measurement; Proportional Hazards Models; Prospective Studies; Remission Induction; Treatment Outcome; Wound Healing; Zoledronic Acid | 2012 |
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2011 |
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Japan; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Treatment Outcome; Triazoles; Zoledronic Acid | 2012 |
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Arthralgia; Bone Marrow Cells; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Treatment Outcome; Zoledronic Acid | 2012 |
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Estradiol; Female; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Tamoxifen; Triazoles; Zoledronic Acid | 2012 |
Treatment of bone metastases before the onset of pain.
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Randomized Controlled Trials as Topic; Zoledronic Acid | 2013 |
Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Zoledronic Acid | 2012 |
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.
Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Gingiva; Humans; Hyperbaric Oxygenation; Imidazoles; Male; Multiple Myeloma; Osteoporosis; Pain Management; Pamidronate; Prospective Studies; Quality of Life; Treatment Outcome; Wound Healing; Zoledronic Acid | 2012 |
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Quality of Life; RANK Ligand; Zoledronic Acid | 2012 |
Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
Topics: Analgesics; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Pain; Zoledronic Acid | 2013 |
(89)Sr imaging with bremsstrahlung in patients with metastatic breast cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Electromagnetic Radiation; Female; Humans; Imidazoles; Middle Aged; Pain Management; Radionuclide Imaging; Strontium Radioisotopes; Zoledronic Acid | 2012 |
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Postmenopause; Triazoles; Zoledronic Acid | 2013 |
Bisphosphonates and metastatic breast carcinoma.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Forecasting; Glycoproteins; Humans; Imidazoles; Infusions, Intravenous; Osteoprotegerin; Pamidronate; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Zoledronic Acid | 2003 |
Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2002 |
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Kidney; Male; Multiple Myeloma; Neoplasm Metastasis; Placebos; Prostatic Neoplasms; Time Factors; United States; United States Food and Drug Administration; Zoledronic Acid | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2003 |
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2004 |
Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.
Topics: Bone Neoplasms; Breast Neoplasms; Canada; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Middle Aged; Outcome and Process Assessment, Health Care; Pamidronate; Prospective Studies; Quality of Life; United States; Zoledronic Acid | 2004 |
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
Topics: Aged; Arthralgia; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Creatinine; Diphosphonates; Fatigue; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Nausea; Pain; Pain Measurement; Prospective Studies; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid | 2004 |
A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Treatment Outcome; Zoledronic Acid | 2005 |
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Japan; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2005 |
Zoledronic acid prevents cancer treatment-induced bone loss.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2005 |
Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
Topics: Activities of Daily Living; Adult; Aged; Bone Neoplasms; Breast Neoplasms; Cross-Over Studies; Diphosphonates; Emotions; Female; Hospitals, Community; Humans; Imidazoles; Infusions, Intravenous; Inpatients; Middle Aged; Outpatients; Pain; Pain Measurement; Quality of Life; Zoledronic Acid | 2005 |
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
Topics: Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cytokines; Diphosphonates; Female; Fibroblast Growth Factor 2; Humans; Imidazoles; Interferon-gamma; Interleukins; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Metalloproteases; Middle Aged; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2005 |
CALGB 78909: Phase III trial of intravenous zoledronic acid in the prevention of bone loss in localized breast cancer patients with chemotherapy-induced ovarian failure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Resorption; Breast Neoplasms; Clinical Protocols; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Primary Ovarian Insufficiency; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
S0307. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Predictive Value of Tests; Survival Rate; Zoledronic Acid | 2005 |
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Disease Progression; Drug Resistance; Female; Humans; Imidazoles; Middle Aged; Pain; Palliative Care; Pamidronate; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2006 |
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Density; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Peptides; Triazoles; Zoledronic Acid | 2007 |
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid | 2007 |
Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Osteocalcin; Peptide Fragments; Peptides; Procollagen; Zoledronic Acid | 2007 |
Zoledronic acid treatment at home: safety data from an observational prospective trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Home Care Services; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Multiple Myeloma; Observation; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Time Factors; Zoledronic Acid | 2007 |
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Creatinine; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Osteoclasts; Osteolysis; Pamidronate; Peptides; Retrospective Studies; Risk Assessment; Survival Rate; Treatment Outcome; Zoledronic Acid | 2007 |
The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Musculoskeletal System; Quality of Life; Zoledronic Acid | 2007 |
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Triazoles; Zoledronic Acid | 2008 |
[Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study].
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Pain; Pilot Projects; Prognosis; Zoledronic Acid | 2008 |
In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lymphocyte Subsets; Middle Aged; Neoplasm Staging; Receptors, Antigen, T-Cell, alpha-beta; T-Lymphocytes; Zoledronic Acid | 2009 |
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Calcium; Circadian Rhythm; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteocalcin; Parathyroid Hormone; Peptides; Zoledronic Acid | 2008 |
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Collagen; Collagen Type I; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Pamidronate; Peptides; Zoledronic Acid | 2001 |
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pamidronate; Time Factors; Zoledronic Acid | 2001 |
332 other study(ies) available for zoledronic acid and Breast Cancer
| Article | Year |
|---|---|
Initiation of bone-targeted agents in patients with bone metastases and breast or castrate-resistant prostate cancer actively treated in routine clinical practice in Europe.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Germany; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2022 |
Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer-Reply.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Zoledronic Acid | 2022 |
Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Zoledronic Acid | 2022 |
Reduced Expression of Natural Killer Cell-Related Activating Receptors by Peripheral Blood Mononuclear Cells from Patients with Breast Cancer and Their Improvement by Zoledronic Acid.
Topics: Breast Neoplasms; Female; Humans; Leukocytes, Mononuclear; Natural Cytotoxicity Triggering Receptor 1; NK Cell Lectin-Like Receptor Subfamily K; Phytohemagglutinins; Receptors, KIR2DL1; Receptors, Natural Killer Cell; Zoledronic Acid | 2022 |
Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Child; Child, Preschool; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Prospective Studies; Spinal Fractures; Zoledronic Acid | 2022 |
Intravascular Administration of Acridine Orange and Zoledronate in a Bone Metastasis Model of Breast Cancer.
Topics: Acridine Orange; Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; DNA Nucleotidylexotransferase; Female; Imidazoles; Mice; Osteolysis; X-Ray Microtomography; Zoledronic Acid | 2022 |
Uveitis, a rare but important complication of adjuvant zoledronic acid for early-stage breast cancer.
Topics: Adjuvants, Immunologic; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Uveitis; Zoledronic Acid | 2023 |
Adjuvant zoledronic acid therapy for postmenopausal women with early breast cancer in China: a cost-effectiveness analysis.
Topics: Aromatase Inhibitors; Breast Neoplasms; China; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Female; Humans; Postmenopause; Quality-Adjusted Life Years; Zoledronic Acid | 2023 |
Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Retrospective Studies; Zoledronic Acid | 2023 |
Denosumab and Zoledronic Acid Differently Affect Circulating Immune Subsets: A Possible Role in the Onset of MRONJ.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclins; Denosumab; Female; Humans; Respiratory Distress Syndrome; Zoledronic Acid | 2023 |
Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium, Dietary; Denosumab; Dietary Supplements; Female; Germany; Guideline Adherence; Humans; Lung Neoplasms; Male; Oncologists; Practice Patterns, Physicians'; Prostatic Neoplasms; Retrospective Studies; Surveys and Questionnaires; Vitamin D; Vitamins; Zoledronic Acid | 2020 |
Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Insulin; Insulin-Like Growth Factor I; Menopause; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptor, IGF Type 1; Survival Analysis; Zoledronic Acid | 2019 |
Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Topics: Ankle; Anorexia; Antithyroid Agents; Aromatase Inhibitors; Arthralgia; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Collagen Type I; Denosumab; Deprescriptions; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Graves Disease; Humans; Hypercalcemia; Methimazole; Middle Aged; Parathyroid Hormone; Peptides; Potassium Iodide; Radionuclide Imaging; Tartrate-Resistant Acid Phosphatase; Thirst; Zoledronic Acid | 2020 |
Bone modifying agents for patients with bone metastases from breast cancer managed in routine practice setting: Treatment patterns and outcome.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Middle Aged; Retrospective Studies; Zoledronic Acid | 2020 |
Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Humans; Letrozole; Liver; Middle Aged; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Zoledronic Acid | 2020 |
Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy.
Topics: Absorptiometry, Photon; Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Marrow; Breast Neoplasms; Cancellous Bone; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Lumbar Vertebrae; Magnetic Resonance Imaging; Middle Aged; Osteoporosis; Postmenopause; Zoledronic Acid | 2019 |
Metal-Organic Framework Nanoparticles for Ameliorating Breast Cancer-Associated Osteolysis.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Humans; Metal-Organic Frameworks; Mice; Nanoparticles; Oligodeoxyribonucleotides; Osteoclasts; Osteolysis; Tumor-Associated Macrophages; Zoledronic Acid | 2020 |
Mesenchymal stromal cells administration for osteonecrosis of the jaw caused by bisphosphonate: report of two cases.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Male; Mesenchymal Stem Cell Transplantation; Multiple Myeloma; Zoledronic Acid | 2020 |
Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Denosumab; Female; Humans; Middle Aged; Neoplasm Metastasis; Osteolysis; Pamidronate; Prognosis; Radiotherapy, Conformal; Retrospective Studies; Spine; Zoledronic Acid | 2020 |
Association of Behavioral Nudges With High-Value Evidence-Based Prescribing in Oncology.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Choice Behavior; Denosumab; Female; Humans; Lung Neoplasms; Male; Medical Oncology; Middle Aged; Oncologists; Practice Patterns, Physicians'; Prostatic Neoplasms; Zoledronic Acid | 2020 |
A case of delayed-onset scarring alopecia in a 75-year-old woman.
Topics: Aged; Alopecia; Anastrozole; Aromatase Inhibitors; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Cicatrix; Diagnosis, Differential; Drug Therapy, Combination; Erythema; Female; Humans; Immunohistochemistry; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyridines; Scalp; Telangiectasis; Zoledronic Acid | 2020 |
Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment.
Topics: Breast Neoplasms; Cell Differentiation; Cell Proliferation; Cell Survival; Female; Graphite; Humans; MCF-7 Cells; Nanostructures; Neoplasm Metastasis; Osteoporosis; Zoledronic Acid | 2020 |
Symptomatic hypocalcemia following a single dose of zoledronic acid in a patient with bone metastases secondary to breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Hypocalcemia; Hypophosphatemia; Magnetic Resonance Imaging; Middle Aged; Positron-Emission Tomography; Vitamin D Deficiency; Zoledronic Acid | 2021 |
Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13).
Topics: Adult; Aged; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Cytokines; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Taxoids; Zoledronic Acid | 2021 |
Intractable Fractures of the Bilateral Proximal Ulnae After 8 Years of Zoledronate Treatment for Breast Cancer Bone Metastasis.
Topics: Bone Neoplasms; Bone Plates; Breast Neoplasms; Female; Fracture Fixation, Internal; Humans; Ulna; Ulna Fractures; Zoledronic Acid | 2022 |
Adjuvant Zoledronate Therapy for Women With Breast Cancer-Effective Treatment or Fool's Gold?
Topics: Breast Neoplasms; Combined Modality Therapy; Female; Humans; Zoledronic Acid | 2021 |
Breast cancer therapy and bone.
Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Neoplasm Recurrence, Local; Zoledronic Acid | 2022 |
Wenshen Zhuanggu formula effectively suppresses breast cancer bone metastases in a mouse Xenograft model.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoclasts; Plant Extracts; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |
Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer - Results from the prospective German Tumour Registry Breast Cancer cohort study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Drug Substitution; Female; Germany; Humans; Imidazoles; Middle Aged; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Survival Analysis; Young Adult; Zoledronic Acid | 2017 |
Use of Leukocyte- and Platelet-Rich Fibrin in the Treatment of Medication-Related Osteonecrosis of the Jaws.
Topics: Aged; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Debridement; Female; Humans; Leukocytes; Membranes, Artificial; Platelet-Rich Fibrin; Suture Techniques; Zoledronic Acid | 2018 |
Acute Bilateral Anterior Uveitis after a Single Intravenous Infusion of Zoledronic Acid in Metastatic Breast Cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Uveitis, Anterior; Zoledronic Acid | 2017 |
Targeting Osteocytes to Attenuate Early Breast Cancer Bone Metastasis by Theranostic Upconversion Nanoparticles with Responsive Plumbagin Release.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Female; Gadolinium; Humans; Luminescent Agents; Mice; Mice, Nude; Nanoparticles; Naphthoquinones; Optical Imaging; Osteocytes; Silicon Dioxide; Theranostic Nanomedicine; Zoledronic Acid | 2017 |
Bone targeted therapies in advanced breast cancer
Topics: Administration, Intravenous; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2017 |
VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer.
Topics: Anticholesteremic Agents; Apoptosis; Biomarkers, Tumor; Bone Density Conservation Agents; Breast Neoplasms; Cell Movement; Cell Proliferation; Diphosphonates; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Imidazoles; Indoles; Protein Interaction Maps; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2018 |
Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; DNA, Neoplasm; Estradiol; Female; Humans; Imidazoles; MCF-7 Cells; Neoplasms, Hormone-Dependent; Zoledronic Acid | 2017 |
Sequential Delivery of Doxorubicin and Zoledronic Acid to Breast Cancer Cells by CB[7]-Modified Iron Oxide Nanoparticles.
Topics: Breast Neoplasms; Doxorubicin; Drug Delivery Systems; Ferric Compounds; HEK293 Cells; Humans; MCF-7 Cells; Metal Nanoparticles; Zoledronic Acid | 2017 |
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Medical Oncology; Ontario; Pain; Pamidronate; Societies, Medical; United States; Zoledronic Acid | 2017 |
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
Adjuvant zoledronic acid to treat breast cancer: not for all.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Humans; Imidazoles; Zoledronic Acid | 2017 |
A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow.
Topics: Animals; Bone Marrow; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Humans; Imidazoles; Male; Mesenchymal Stem Cells; Mice, Mutant Strains; Parathyroid Hormone; Prenylation; Prostatic Neoplasms; Stem Cell Niche; Xenograft Model Antitumor Assays; Zoledronic Acid | 2018 |
Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer.
Topics: Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Disseminated Intravascular Coagulation; Female; Humans; Imidazoles; Middle Aged; Treatment Outcome; Zoledronic Acid | 2018 |
[Relapse of chronic inflammatory demyelinating polyneuropathy following treatment with zoledronic acid].
Topics: Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Recurrence, Local; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Zoledronic Acid | 2017 |
Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer.
Topics: Bone and Bones; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Zoledronic Acid | 2018 |
Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer.
Topics: Bone and Bones; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Zoledronic Acid | 2018 |
Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer-Reply.
Topics: Bone and Bones; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Zoledronic Acid | 2018 |
Longitudinal resting-state functional magnetic resonance imaging in a mouse model of metastatic bone cancer reveals distinct functional reorganizations along a developing chronic pain state.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chronic Pain; Disease Models, Animal; Female; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Oxygen; Pain Measurement; Rest; Zoledronic Acid | 2018 |
Reply to L. Kennedy et al.
Topics: Breast Neoplasms; Cost-Benefit Analysis; Denosumab; Female; Humans; Zoledronic Acid | 2018 |
Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Humans; Zoledronic Acid | 2018 |
Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Drug Synergism; Estradiol; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Gene Expression; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Mice; Models, Biological; Signal Transduction; Xenograft Model Antitumor Assays; Zoledronic Acid | 2018 |
Inhibition of UGT8 suppresses basal-like breast cancer progression by attenuating sulfatide-αVβ5 axis.
Topics: Animals; Biosynthetic Pathways; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Movement; Disease Progression; Female; Ganglioside Galactosyltransferase; Gene Expression Regulation, Neoplastic; Humans; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Receptors, Vitronectin; Signal Transduction; SOXE Transcription Factors; Sulfoglycosphingolipids; Survival Analysis; Up-Regulation; Zoledronic Acid | 2018 |
Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw.
Topics: Actinomyces; Aged; Aged, 80 and over; Bacterial Infections; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Male; Middle Aged; Prevotella; Prostatic Neoplasms; Streptococcus; Veillonella; Zoledronic Acid | 2019 |
Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Chemotherapy, Adjuvant; Female; Gene Knockdown Techniques; GTPase-Activating Proteins; Humans; Middle Aged; Neoplasm Grading; Neoplasm Proteins; Prognosis; Proteomics; Risk Assessment; Tumor Cells, Cultured; Up-Regulation; Young Adult; Zoledronic Acid | 2019 |
Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years.
Topics: Aged; Antineoplastic Agents, Hormonal; Asian People; Bone Density; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Denosumab; Female; Follow-Up Studies; Hong Kong; Humans; Incidence; Mastectomy; Middle Aged; Postmenopause; Radiotherapy, Adjuvant; Receptors, Estrogen; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid | 2018 |
Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Middle Aged; United States; Zoledronic Acid | 2019 |
Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
Topics: Aged; Breast Neoplasms; CD8-Positive T-Lymphocytes; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Therapy; Female; Histocompatibility Antigens Class I; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tumor Microenvironment; Zoledronic Acid | 2019 |
Bone-Targeted Nanoplatform Combining Zoledronate and Photothermal Therapy To Treat Breast Cancer Bone Metastasis.
Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Proliferation; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred ICR; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Optical Imaging; Particle Size; Phototherapy; Porosity; Surface Properties; Tumor Cells, Cultured; Tumor Microenvironment; Zoledronic Acid | 2019 |
Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Breast Neoplasms; Cattle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Humans; Zoledronic Acid | 2019 |
New evidence and hope for young patients with breast cancer.
Topics: Adaptation, Psychological; Breast Neoplasms; Hope; Humans; Letrozole; Zoledronic Acid | 2019 |
Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Caspases; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Cisplatin; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imidazoles; Inhibitory Concentration 50; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Zoledronic Acid | 2013 |
[A case of recurrent breast cancer with multiple bone metastasis successfully treated with S-1 and zoledronic acid therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Combinations; Female; Humans; Imidazoles; Oxonic Acid; Recurrence; Tegafur; Zoledronic Acid | 2013 |
Promise and perils of guidelines in quality cancer care.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Ethics, Medical; Evidence-Based Medicine; Female; Guideline Adherence; Humans; Imidazoles; Middle Aged; North Carolina; Patient Preference; Practice Guidelines as Topic; Quality of Health Care; Secondary Prevention; Zoledronic Acid | 2012 |
[Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction].
Topics: Adult; Aged; Aged, 80 and over; Benchmarking; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Feasibility Studies; Female; Home Infusion Therapy; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Nurse-Patient Relations; Nursing Staff; Patient Compliance; Patient Satisfaction; Personal Satisfaction; Prospective Studies; Prostatic Neoplasms; Surveys and Questionnaires; Zoledronic Acid | 2013 |
Does zoledronic acid have additive effect on suppression of plasma estrogen levels?
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Synergism; Estrogens; Female; Humans; Imidazoles; Letrozole; Nitriles; Triazoles; Zoledronic Acid | 2013 |
Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Mucin-1; Peptide Fragments; Peptides; Procollagen; Zoledronic Acid | 2013 |
Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB.
Topics: Breast Neoplasms; Diphosphonates; Epithelial-Mesenchymal Transition; Female; Humans; Imidazoles; NF-kappa B; Signal Transduction; Zoledronic Acid | 2013 |
Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cachexia; Cell Proliferation; Diphosphonates; Disease Models, Animal; DNA Breaks, Double-Stranded; DNA, Neoplasm; Doxorubicin; Female; Imidazoles; Kaplan-Meier Estimate; Mice; Osteoblasts; Osteoclasts; Radioisotopes; Radium; Stem Cells; Tumor Cells, Cultured; Zoledronic Acid | 2013 |
Zooming in on the schedule of bone-modifying drugs.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2013 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neoplasms; Breast Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fixatives; Fluorouracil; Formaldehyde; Humans; Imidazoles; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon; Triazoles; Zoledronic Acid | 2013 |
Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Caspases; Cell Adhesion; Cell Differentiation; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Chemokine CCL2; Chemokines; Diphosphonates; Extracellular Matrix; Female; Gene Expression Regulation; Genetic Markers; Humans; Imidazoles; Osteoblasts; Zoledronic Acid | 2013 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Arthritis, Rheumatoid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diabetes Complications; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Parenteral; Japan; Male; Middle Aged; Oral Surgical Procedures; Osteoporosis; Prostatic Neoplasms; Risedronic Acid; Treatment Outcome; Wound Healing; Zoledronic Acid | 2013 |
Zoledronic acid-induced cytotoxicity through endoplasmic reticulum stress triggered REDD1-mTOR pathway in breast cancer cells.
Topics: Base Sequence; Bone Density Conservation Agents; Breast Neoplasms; Cell Division; Diphosphonates; DNA Primers; Endoplasmic Reticulum; Female; Humans; Imidazoles; MCF-7 Cells; Polymerase Chain Reaction; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Zoledronic Acid | 2013 |
Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion.
Topics: Animals; Breast Neoplasms; Cell Communication; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Diphosphonates; Female; Humans; Imidazoles; Macrophages; Matrix Metalloproteinases; MCF-7 Cells; Mice; Microglia; Tumor Microenvironment; Zoledronic Acid | 2013 |
Percutaneous vertebroplasty combined with zoledronic acid for the treatment of painful osteolytic spinal metastases in patients with breast cancer.
Topics: Adult; Aged; Back Pain; Bone Density Conservation Agents; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Karnofsky Performance Status; Middle Aged; Osteolysis; Pain Measurement; Quality of Life; Retrospective Studies; Spinal Neoplasms; Surveys and Questionnaires; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2013 |
Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Humans; Imidazoles; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Prenylation; rap1 GTP-Binding Proteins; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid | 2013 |
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Heterografts; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; X-Ray Microtomography; Zoledronic Acid | 2013 |
The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphosphonates; Drug Screening Assays, Antitumor; Etidronic Acid; Female; Humans; Imidazoles; Inhibitory Concentration 50; Neoplasm Invasiveness; Pamidronate; Risedronic Acid; Zoledronic Acid | 2014 |
Quality of life assessment in Taiwanese patients with bone metastases from breast cancer receiving zoledronic acid.
Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Quality of Life; Taiwan; Zoledronic Acid | 2013 |
Which bisphosphonate to treat bone metastases?
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Zoledronic Acid | 2014 |
Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2014 |
[A case of facial nerve palsy induced by nab-paclitaxel].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphosphonates; Facial Paralysis; Female; Humans; Imidazoles; Middle Aged; Paclitaxel; Zoledronic Acid | 2013 |
[Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcium; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Postmenopause; Vitamin D; Zoledronic Acid | 2013 |
Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?
Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Femur; Frontal Bone; Germany; Humans; Imidazoles; Male; Mandible; Maxilla; Middle Aged; Prostatic Neoplasms; Radionuclide Imaging; Retrospective Studies; Sex Factors; Zoledronic Acid | 2014 |
Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?
Topics: Adult; Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Femur; Follow-Up Studies; Frontal Bone; Humans; Imidazoles; Jaw; Mandible; Maxilla; Middle Aged; Radionuclide Imaging; Radiopharmaceuticals; Retrospective Studies; Technetium Compounds; Whole Body Imaging; Zoledronic Acid | 2014 |
[Long-term results of personalized treatment in 72 breast cancer patients who failed chemotherapy].
Topics: Adult; Aged; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diphosphonates; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Lung Neoplasms; Medicine, Chinese Traditional; Middle Aged; Neoplasm Staging; Nitriles; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Rate; Treatment Failure; Triazoles; Zoledronic Acid | 2013 |
Synchronous antiresorptive osteonecrosis of the jaws and breast cancer metastasis.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diagnostic Imaging; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Maxillary Neoplasms; Middle Aged; Zoledronic Acid | 2014 |
Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Carcinoma; Denosumab; Diphosphonates; Female; Femur; Frontal Bone; Humans; Image Processing, Computer-Assisted; Imidazoles; Jaw Diseases; Mandible; Maxilla; Middle Aged; Osteonecrosis; Radionuclide Imaging; RANK Ligand; Retrospective Studies; Zoledronic Acid | 2014 |
Characterization of the attenuation of breast cancer bone metastasis in mice by zoledronic acid using (99m)Tc bone scintigraphy.
Topics: Animals; Biomarkers, Tumor; Blotting, Western; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Radionuclide Imaging; Radiopharmaceuticals; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Technetium Tc 99m Medronate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |
Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cellular Microenvironment; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Osteoclasts; Ovariectomy; Postmenopause; Premenopause; Real-Time Polymerase Chain Reaction; X-Ray Microtomography; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |
Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
Topics: Aged; Ambulatory Care; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Canada; Costs and Cost Analysis; Cross-Sectional Studies; Diphosphonates; Equipment and Supplies; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Pamidronate; Prospective Studies; Prostatic Neoplasms; Time Factors; Zoledronic Acid | 2014 |
Bisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: a case report solved with non-invasive treatment.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Mouthwashes; Radiography, Panoramic; Time Factors; Tooth Extraction; Treatment Outcome; Zoledronic Acid | 2014 |
Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Topics: Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Green Fluorescent Proteins; Humans; Imidazoles; Immunocompromised Host; Mice, Inbred BALB C; Mice, Nude; Organ Size; Osteoblasts; Osteoclasts; Reproducibility of Results; Zoledronic Acid | 2014 |
Fluorodeoxyglucose positron emission tomography with computed tomography detects greater metabolic changes that are not represented by plain radiography for patients with osteonecrosis of the jaw.
Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Cross-Sectional Studies; Diphosphonates; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiography, Bitewing; Radiography, Panoramic; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Tooth Extraction; Zoledronic Acid | 2014 |
Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).
Topics: Biomarkers; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Neoplastic Cells, Circulating; Proportional Hazards Models; Treatment Outcome; Zoledronic Acid | 2014 |
Randomized clinical trials and observational studies are more often alike than unlike.
Topics: Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2014 |
Auto-fluorescence of the bone and its use for delineation of bone necrosis.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Optical Imaging; Prostatic Neoplasms; Zoledronic Acid | 2014 |
In vitro and in vivo effects of photodynamic therapy on metastatic breast cancer cells pre-treated with zoledronic acid.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; In Vitro Techniques; Photochemotherapy; Photosensitizing Agents; Rats; Rats, Nude; Treatment Outcome; Zoledronic Acid | 2014 |
Spontaneous acetabular periprosthetic fracture in a patient continuously having zoledronic acid.
Topics: Acetabulum; Aged; Arthroplasty, Replacement, Hip; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Fractures, Spontaneous; Hip Prosthesis; Humans; Imidazoles; Osteoarthritis, Hip; Periprosthetic Fractures; Prosthesis Failure; Reoperation; Zoledronic Acid | 2014 |
Breast cancer: Zoledronic acid--more than just a bone drug.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2014 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid | 2015 |
The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Topics: Administration, Metronomic; Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Camellia sinensis; Cell Line, Tumor; Diphosphonates; Drug Therapy, Combination; Female; Imidazoles; Liver Neoplasms; Luminescent Measurements; Lung Neoplasms; Mammary Neoplasms, Experimental; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Osteolysis; Plant Extracts; Zoledronic Acid | 2015 |
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Connexins; Diphosphonates; Etidronic Acid; Female; Hemiterpenes; Humans; Ibandronic Acid; Imidazoles; MCF-7 Cells; Multidrug Resistance-Associated Proteins; Nerve Tissue Proteins; Organophosphorus Compounds; Osteoclasts; Phosphate Transport Proteins; Probenecid; Risedronic Acid; Zoledronic Acid | 2014 |
Liposome encapsulated zoledronate favours M1-like behaviour in murine macrophages cultured with soluble factors from breast cancer cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Diphosphonates; Female; Humans; Imidazoles; Liposomes; Macrophages; Matrix Metalloproteinases; Mice; Nitric Oxide Synthase Type II; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2015 |
Oxidative stress plays an important role in zoledronic acid-induced autophagy.
Topics: Autophagy; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Humans; Imidazoles; MCF-7 Cells; Mevalonic Acid; Oxidative Stress; Zoledronic Acid | 2014 |
[Two cases of dural metastasis of breast cancer].
Topics: Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemoradiotherapy; Diphosphonates; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Zoledronic Acid | 2014 |
The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway.
Topics: Activins; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Female; Follistatin; Humans; Imidazoles; MCF-7 Cells; Mice; Phosphorylation; Receptors, Estrogen; Signal Transduction; Smad2 Protein; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Letrozole; MAP Kinase Signaling System; Mice; Mice, Nude; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Nitriles; Postmenopause; Receptors, Estrogen; RNA Interference; RNA, Small Interfering; Transcription, Genetic; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Extracellular Ca(2+)-dependent enhancement of cytocidal potency of zoledronic acid in human oral cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Calcium; Calcium Chelating Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Cytochromes c; Diphosphonates; Dose-Response Relationship, Drug; Head and Neck Neoplasms; Humans; Imidazoles; MCF-7 Cells; Membrane Potential, Mitochondrial; Mitochondria; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck; Zoledronic Acid | 2015 |
VALIDATION OF THERAPEUTIC RESPONSE ASSESSMENT BY BONE SCINTIGRAPHY IN PATIENTS WITH BONE-ONLY METASTATIC BREAST CANCERS DURING ZOLEDRONIC ACID TREATMENT: COMPARISON WITH COMPUTED TOMOGRAPHY ASSESSMENT.
Topics: Adult; Aged; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Zoledronic Acid | 2015 |
Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Logistic Models; Middle Aged; Retrospective Studies; Risk Factors; Trastuzumab; Treatment Outcome; Zoledronic Acid | 2015 |
Polyoxomolybdate Bisphosphonate Heterometallic Complexes: Synthesis, Structure, and Activity on a Breast Cancer Cell Line.
Topics: Breast Neoplasms; Cell Line; Crystallography, X-Ray; Diphosphonates; Humans; Imidazoles; Iron; Ligands; Magnetic Resonance Spectroscopy; Manganese; Molybdenum; Organometallic Compounds; Oxidation-Reduction; Zoledronic Acid | 2015 |
Human stromal cells are required for an anti-breast cancer effect of zoledronic acid.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chickens; Chorioallantoic Membrane; Coculture Techniques; Diphosphonates; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitory Concentration 50; MCF-7 Cells; Microscopy, Fluorescence; Phosphorylation; Signal Transduction; Smad2 Protein; Stromal Cells; Transforming Growth Factor beta; Tumor Microenvironment; Zoledronic Acid | 2015 |
Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Density Conservation Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Diphosphonates; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Naphthoquinones; Proto-Oncogene Proteins c-bcl-2; Receptor, Notch1; RNA, Small Interfering; Signal Transduction; Zoledronic Acid | 2015 |
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Topics: Adjuvants, Pharmaceutic; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis; Triazoles; Zoledronic Acid | 2016 |
Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages.
Topics: Animals; Bone Density Conservation Agents; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Chemokine CCL2; Cytokines; Diphosphonates; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Immunohistochemistry; Lectins, C-Type; Luciferases; Luminescent Measurements; Macrophages; Mammary Neoplasms, Experimental; Mannose Receptor; Mannose-Binding Lectins; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice, Inbred C57BL; Mice, Nude; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Humans; Imidazoles; Marine Toxins; MCF-7 Cells; Okadaic Acid; Oxazoles; Phosphatidylinositol 3-Kinases; Phosphoprotein Phosphatases; Proto-Oncogene Proteins c-akt; Signal Transduction; Zoledronic Acid | 2016 |
Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Mevalonic Acid; Mice, Nude; Osteoblasts; Rosuvastatin Calcium; Simvastatin; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Diphosphonates; Disease Models, Animal; Female; Hemiterpenes; Humans; Hyperthermia, Induced; Imidazoles; Organophosphorus Compounds; rap1 GTP-Binding Proteins; Ultrasonic Waves; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Estradiol; Female; Flow Cytometry; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Receptors, Estrogen; Tumor Microenvironment; X-Ray Microtomography; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.
Topics: Adaptor Proteins, Signal Transducing; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Microfilament Proteins; Molecular Targeted Therapy; Nuclear Proteins; Odds Ratio; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Reproducibility of Results; Zoledronic Acid | 2016 |
Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Models, Theoretical; Neoplasm Recurrence, Local; Receptors, Estrogen; Zoledronic Acid | 2016 |
Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
Topics: Adenine Nucleotides; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Drug Synergism; Female; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthoquinones; Osteoclasts; Osteolysis; Phosphorylation; Random Allocation; Signal Transduction; Zoledronic Acid | 2016 |
The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Diphosphonates; Female; Humans; Imidazoles; MicroRNAs; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Zoledronic Acid | 2016 |
Uptake of free, calcium-bound and liposomal encapsulated nitrogen containing bisphosphonates by breast cancer cells.
Topics: Breast Neoplasms; Calcium; Cell Line, Tumor; Diphosphonates; Endocytosis; Female; Humans; Imidazoles; Liposomes; Nitrogen; Risedronic Acid; Zoledronic Acid | 2016 |
Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; Biosynthetic Pathways; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Diphosphonates; Drug Synergism; Enzyme Activation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Mevalonic Acid; rho GTP-Binding Proteins; Zoledronic Acid | 2016 |
Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Middle Aged; Pamidronate; Proportional Hazards Models; Retrospective Studies; Risk Factors; Zoledronic Acid | 2016 |
Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Density Conservation Agents; Breast Neoplasms; Cell Proliferation; Diphosphonates; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Immune Tolerance; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
Efficacy of zoledronic acid in Erdheim-Chester disease: A case report.
Topics: Aged; Bone Density Conservation Agents; Bone Diseases; Breast Neoplasms; Diphosphonates; Erdheim-Chester Disease; Female; Follow-Up Studies; Humans; Imidazoles; Zoledronic Acid | 2016 |
Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Collagen Type I; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Peptides; Retrospective Studies; Tartrate-Resistant Acid Phosphatase; Treatment Outcome; Zoledronic Acid | 2017 |
Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Gene Expression Profiling; Humans; Imidazoles; MCF-7 Cells; Transcriptome; Zoledronic Acid | 2016 |
Autofluorescence as indicator for detecting the surgical margins of medication-related osteonecrosis of the jaws.
Topics: Aged; Aged, 80 and over; Bicuspid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Breast Neoplasms; Cementoplasty; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Laser Therapy; Lasers, Solid-State; Lung Neoplasms; Male; Margins of Excision; Middle Aged; Multiple Myeloma; Optical Imaging; Postoperative Complications; Tooth Extraction; Zoledronic Acid | 2016 |
Anti-cancer effects of nitrogen-containing bisphosphonates on human cancer cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Bone Density Conservation Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Imidazoles; MCF-7 Cells; Mice; Neoplasm Transplantation; Nitrogen; Zoledronic Acid | 2016 |
N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Metastasis; Peptides; Prognosis; Prospective Studies; Receptors, Estrogen; Zoledronic Acid | 2016 |
Mono- and Combined Therapy of Metastasizing Breast Carcinoma 4T1 with Zoledronic Acid and Doxorubicin.
Topics: Animals; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Doxorubicin; Female; Imidazoles; Magnetic Resonance Imaging; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Zoledronic Acid | 2016 |
Increased CD14+ and decreased CD14- populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Separation; Diphosphonates; Female; Flow Cytometry; Follow-Up Studies; Humans; Imidazoles; Immunophenotyping; Leukocytes; Lipopolysaccharide Receptors; Middle Aged; Monocytes; Prospective Studies; Zoledronic Acid | 2017 |
Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Lung Neoplasms; Lymphocyte Activation; Mice, Inbred NOD; Mice, SCID; Osteolysis; Phenotype; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes, Cytotoxic; Time Factors; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |
Immune modulation of CD4
Topics: Breast Neoplasms; Cancer Vaccines; CD4 Antigens; Cell Movement; Cells, Cultured; Coculture Techniques; Diphosphonates; Female; Humans; Imidazoles; Immunologic Factors; Immunotherapy; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; NF-kappa B; Osteogenesis; RANK Ligand; Signal Transduction; T-Lymphocytes, Regulatory; Th17 Cells; Zoledronic Acid | 2016 |
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Progression; Estradiol; Female; Humans; Imidazoles; Letrozole; Mice, Inbred BALB C; Mice, Nude; Muscle Strength; Muscle Weakness; Muscle, Skeletal; Nitriles; Osteolysis; Ovariectomy; Receptors, Estrogen; Time Factors; Triazoles; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Letrozole; Lymph Node Excision; Lymph Nodes; Mastectomy; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy; Ribs; Taxoids; Triazoles; Zoledronic Acid | 2017 |
Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Diphosphonates; Disease Progression; Enzyme Activation; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Models, Biological; Multimodal Imaging; Osteoclasts; Tumor Burden; Tumor Microenvironment; Zoledronic Acid | 2017 |
Less Intense Dosing Schedule for a Bone-Modifying Agent.
Topics: Breast Neoplasms; Drug Administration Schedule; Female; Humans; Zoledronic Acid | 2017 |
Bisphosphonate-Related Osteonecrosis and Metastasis Within the Same Site of the Jaw.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Breast Neoplasms; Diagnosis, Differential; Diphosphonates; Fatal Outcome; Female; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Mandible; Mandibular Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Radiography, Panoramic; Tomography, X-Ray Computed; Zoledronic Acid | 2017 |
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Cells; Breast Neoplasms; Cell Line, Tumor; Colony-Forming Units Assay; Diphosphonates; Disease Models, Animal; Extracellular Matrix; Female; Hematopoiesis; Hematopoietic Stem Cells; Humans; Imidazoles; Leukocyte Count; Mice; Neovascularization, Pathologic; Osteoblasts; Osteoclasts; X-Ray Microtomography; Zoledronic Acid | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Colitis, Ulcerative; Data Interpretation, Statistical; Diphosphonates; Female; Gastrointestinal Agents; Humans; Ibandronic Acid; Imidazoles; Intention to Treat Analysis; Male; Medication Adherence; Mesalamine; Models, Statistical; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Treatment Outcome; Zoledronic Acid | 2017 |
Use of intravenous bisphosphonates in older women with breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Multivariate Analysis; Pain; Pamidronate; Prevalence; SEER Program; Survival Rate; United States; Zoledronic Acid | 2008 |
Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
Topics: Adult; Aged; Bone Density Conservation Agents; Breast Neoplasms; Case-Control Studies; Chi-Square Distribution; Dental Care for Chronically Ill; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Logistic Models; Middle Aged; Osteonecrosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2008 |
Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Doxorubicin; Female; Humans; Imidazoles; Immunohistochemistry; Mice; Mice, Nude; Zoledronic Acid | 2008 |
New treatment strategies provide more options for patients with breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Density Conservation Agents; Breast Neoplasms; Capecitabine; Deoxycytidine; Diphosphonates; Female; Fluorouracil; Humans; Imidazoles; Zoledronic Acid | 2008 |
Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Databases, Factual; Diphosphonates; Female; Humans; Imidazoles; Insurance Claim Reporting; Lung Neoplasms; Male; Medical Records; Middle Aged; Prostatic Neoplasms; Retrospective Studies; United States; Zoledronic Acid | 2008 |
Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; Cytokines; Cytotoxicity, Immunologic; Diphosphonates; Female; Humans; Imidazoles; Immunophenotyping; Immunotherapy, Adoptive; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; RNA; T-Lymphocytes; Zoledronic Acid | 2008 |
Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
Topics: Acid Phosphatase; Animals; Bone and Bones; Bone Resorption; Breast Neoplasms; Cell Count; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Female; Humans; Imidazoles; Isoenzymes; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoclasts; Osteolysis; Osteoprotegerin; Radiography; Tartrate-Resistant Acid Phosphatase; Whole Body Imaging; Zoledronic Acid | 2009 |
Comment on: Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Dexamethasone; Diphosphonates; Disease Models, Animal; Female; Glucocorticoids; Humans; Imidazoles; Jaw Diseases; Osteonecrosis; Rats; Tooth Extraction; Zoledronic Acid | 2009 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.
Topics: Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Imidazoles; Incidence; Jaw; Middle Aged; Osteonecrosis; Risk Factors; Zoledronic Acid | 2009 |
[A case of recurrent breast carcinoma metastasis successfully treated with S-1 and zoledronic acid therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Diphosphonates; Drug Combinations; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Neoplasm Metastasis; Oxonic Acid; Recurrence; Tegafur; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2009 |
Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Imidazoles; Indoles; Mevalonic Acid; Middle Aged; Ovarian Neoplasms; Signal Transduction; Tumor Cells, Cultured; Zoledronic Acid | 2009 |
Effects of platelet-derived growth factor, vitamin D and parathyroid hormone on osteoblasts derived from cancer patients on chronic bisphosphonate therapy.
Topics: Aged; Antigens, Differentiation; Bone Density Conservation Agents; Bone Regeneration; Breast Neoplasms; Calcitriol; Cell Differentiation; Cells, Cultured; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Osteoblasts; Parathyroid Hormone; Platelet-Derived Growth Factor; Vitamin D; Zoledronic Acid | 2009 |
Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases.
Topics: Adult; Bone and Bones; Bone Density; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Diphosphonates; Female; Humans; Imidazoles; Medical Oncology; Middle Aged; Neoplasm Metastasis; Osteoblasts; Tomography, X-Ray Computed; Zoledronic Acid | 2009 |
Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.
Topics: Breast Neoplasms; Case-Control Studies; Cell Line, Tumor; Cohort Studies; Cytotoxicity, Immunologic; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Granzymes; Humans; Imidazoles; Immunophenotyping; Interleukin-6; Polymerase Chain Reaction; Polymorphism, Genetic; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2009 |
Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
Topics: Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Data Interpretation, Statistical; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Mesenchymal Stem Cells; Premenopause; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Nitriles; Premenopause; Triazoles; Vitamin D; Vitamins; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Receptor, ErbB-2; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells.
Topics: Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Female; Humans; Imidazoles; Osteoprotegerin; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand; Zoledronic Acid | 2010 |
Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Diphosphonates; Doxorubicin; Drug Administration Schedule; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Kaplan-Meier Estimate; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Reverse Transcriptase Polymerase Chain Reaction; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2010 |
[Primary hyperparathyroidism. An alternative to the surgery].
Topics: Adenoma; Aged, 80 and over; Breast Neoplasms; Carcinoma; Carcinoma, Renal Cell; Cinacalcet; Comorbidity; Contraindications; Diphosphonates; Drug Therapy, Combination; Female; Fluid Therapy; Furosemide; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Imidazoles; Kidney Function Tests; Kidney Neoplasms; Naphthalenes; Parathyroid Neoplasms; Parathyroidectomy; Treatment Refusal; Zoledronic Acid | 2009 |
Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Humans; Imidazoles; Mice; Mice, Nude; Osteoclasts; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays; Zoledronic Acid | 2009 |
Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Mice; Models, Biological; Osteoclasts; Xenograft Model Antitumor Assays; Zoledronic Acid | 2009 |
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2009 |
Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
Topics: Adenosine Triphosphate; Anticarcinogenic Agents; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Down-Regulation; Drug Screening Assays, Antitumor; Farnesol; Female; Gene Expression Regulation, Neoplastic; Hemiterpenes; Humans; Imidazoles; Mevalonic Acid; Organophosphorus Compounds; Zoledronic Acid | 2010 |
The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer.
Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Calcaneus; Case-Control Studies; Cyclophosphamide; Diphosphonates; Doxorubicin; Female; Hip; Humans; Imidazoles; Lumbar Vertebrae; Middle Aged; Premenopause; Primary Ovarian Insufficiency; Prospective Studies; Statistics, Nonparametric; Time Factors; Ultrasonography; Young Adult; Zoledronic Acid | 2009 |
Bisphosphonate-related osteonecrosis of the jaw and left thumb.
Topics: Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Curettage; Diphosphonates; Female; Finger Phalanges; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteonecrosis; Osteotomy; Radiography; Thumb; Zoledronic Acid | 2009 |
Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Pain; Pain Measurement; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2009 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid | 2009 |
Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Markov Chains; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Treatment Outcome; Triazoles; Zoledronic Acid | 2010 |
The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Chromosome Segregation; Diphosphonates; Dose-Response Relationship, Drug; Humans; Imidazoles; Kinetochores; Microfilament Proteins; Microscopy, Fluorescence; Protein Prenylation; Time Factors; Zoledronic Acid | 2011 |
Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Mass Screening; Mastectomy; Nitriles; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid | 2009 |
Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid | 2009 |
Beyond bisphosphonates: photodynamic therapy structurally augments metastatically involved vertebrae and destroys tumor tissue.
Topics: Animals; Bone Development; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Humans; Imidazoles; Necrosis; Photochemotherapy; Photosensitizing Agents; Porphyrins; Rats; Rats, Nude; Spinal Neoplasms; Spine; Time Factors; Verteporfin; X-Ray Microtomography; Xenograft Model Antitumor Assays; Zoledronic Acid | 2010 |
Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Health Care Costs; Health Resources; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Kidney; Kidney Function Tests; Middle Aged; Renal Insufficiency; State Medicine; Zoledronic Acid | 2010 |
Scintigraphic evaluation of mandibular bone turnover in patients with solid tumors receiving zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Risk Factors; Tomography, Emission-Computed; Zoledronic Acid | 2010 |
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Imidazoles; Letrozole; Nitriles; Triazoles; Zoledronic Acid | 2010 |
Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss.
Topics: Absorptiometry, Photon; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Confidence Intervals; Diphosphonates; Female; Fractures, Bone; Health Status Indicators; Humans; Imidazoles; Incidence; Odds Ratio; Risk Factors; Risk Reduction Behavior; Zoledronic Acid | 2010 |
Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Osteonecrosis; Zoledronic Acid | 2010 |
Bisphosphonates in adjuvant treatment of early breast cancer.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Survival Analysis; Zoledronic Acid | 2010 |
Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Diphosphonates; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imidazoles; Leukopenia; Male; Mice; Mice, Nude; Osteoclasts; Osteoprotegerin; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2010 |
Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Bone Neoplasms; Breast Neoplasms; Contrast Media; Diphosphonates; Humans; Imidazoles; Indoles; Longitudinal Studies; Magnetic Resonance Imaging; Pyrroles; Random Allocation; Rats; Rats, Nude; Sunitinib; Xenograft Model Antitumor Assays; Zoledronic Acid | 2010 |
Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Multicenter Studies as Topic; Pain; Pain Measurement; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Spinal Cord Compression; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2010 |
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Costs; Female; Germany; Goserelin; Humans; Imidazoles; Markov Chains; Monte Carlo Method; Multicenter Studies as Topic; National Health Programs; Neoplasms, Multiple Primary; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
[Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid].
Topics: Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Combinations; Humans; Imidazoles; Oxonic Acid; Pleural Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2010 |
Predicting skeletal complications in metastatic breast cancer raises challenges.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Pain; Risk Assessment; Risk Factors; Spinal Cord Compression; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2010 |
Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Imidazoles; Markov Chains; Middle Aged; Premenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Zoledronic Acid | 2010 |
Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases.
Topics: Amino Acid Sequence; Animals; Bone Neoplasms; Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Diphosphonates; Female; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Molecular Sequence Data; RNA, Messenger; Zoledronic Acid | 2011 |
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Jaw; Male; Osteonecrosis; Pamidronate; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2010 |
Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Cell Line, Tumor; Cytotoxicity, Immunologic; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Lymphocyte Activation; Pamidronate; T-Lymphocyte Subsets; T-Lymphocytes; Zoledronic Acid | 2010 |
Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Michigan; Middle Aged; Neoplasm Staging; Population Surveillance; Registries; Retrospective Studies; Risedronic Acid; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2010 |
Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Case-Control Studies; Chi-Square Distribution; Diphosphonates; Female; Haplotypes; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Odds Ratio; Osteonecrosis; Polymorphism, Single Nucleotide; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2011 |
American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Pamidronate; RANK Ligand; Societies, Medical; Survival Rate; Treatment Outcome; Zoledronic Acid | 2011 |
"Disappointing" trial results offer hope for older women with breast cancer.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Estrogens; Female; Humans; Imidazoles; Menopause; Neoplasm Recurrence, Local; Treatment Failure; Zoledronic Acid | 2011 |
Breast cancer bone metastases: denosumab or zoledronic acid?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; RANK Ligand; Zoledronic Acid | 2011 |
CCN1, a candidate target for zoledronic acid treatment in breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cysteine-Rich Protein 61; Diphosphonates; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Morphogenesis; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Signal Transduction; Transcription, Genetic; Zoledronic Acid | 2011 |
Unexpected AZURE results lead to rethink for Zometa(®).
Topics: Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Menopause; Middle Aged; Zoledronic Acid | 2011 |
Zoledronic acid for adjuvant use in patients with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2011 |
Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Diphosphonates; Female; Fluorouracil; Humans; Hypercalcemia; Imidazoles; Leucovorin; Middle Aged; Neoplasm Recurrence, Local; Treatment Failure; Vinblastine; Vinorelbine; Zoledronic Acid | 2011 |
Denosumab for bone metastases from breast cancer: a new therapy option?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Kidney; Osteonecrosis; RANK Ligand; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Collagen Type I; Dental Care; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Osteonecrosis; Peptides; Periodontal Diseases; Radiography, Panoramic; Risk Factors; Tooth Extraction; Zoledronic Acid | 2011 |
A case of acquired Fanconi syndrome induced by zoledronic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Fanconi Syndrome; Female; Humans; Hypercalcemia; Imidazoles; Kidney Function Tests; Middle Aged; Zoledronic Acid | 2011 |
Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Communication; Cell Line; Cell Movement; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Immunoassay; Mesenchymal Stem Cells; Real-Time Polymerase Chain Reaction; Signal Transduction; Zoledronic Acid | 2012 |
[A successful case treated with S-1 and zoledronic acid for multiple bone metastasis of breast cancer].
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Combinations; Female; Humans; Imidazoles; Middle Aged; Oxonic Acid; Quality of Life; Tegafur; Zoledronic Acid | 2011 |
[Effects of zoledronic acid in the treatment of breast cancer].
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Neoadjuvant Therapy; Osteoporosis; Zoledronic Acid | 2011 |
Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Alendronate; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Imidazoles; Inhibitory Concentration 50; Ovarian Neoplasms; Reference Standards; Zoledronic Acid | 2012 |
Awareness and education of patients receiving bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Dental Care; Dentist-Patient Relations; Dentists; Diphosphonates; Drug Labeling; Female; Gastrointestinal Diseases; Health Knowledge, Attitudes, Practice; Health Literacy; Humans; Imidazoles; Injections, Intravenous; Interprofessional Relations; Male; Middle Aged; Osteoporosis; Patient Education as Topic; Physician-Patient Relations; Physicians; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2012 |
Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Cell Nucleus; Diphosphonates; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Imidazoles; Mice; Mice, Nude; Neoplasm Proteins; NFATC Transcription Factors; Pancreatic Neoplasms; Phosphorylation; Protein Stability; Protein Structure, Tertiary; Proto-Oncogene Proteins c-mdm2; Signal Transduction; Ubiquitination; Zoledronic Acid | 2011 |
High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
Topics: Adenosine Triphosphate; Animals; Antigens, Neoplasm; Breast Neoplasms; Cell Line, Tumor; Cytotoxicity, Immunologic; Diphosphonates; Female; Hemiterpenes; Humans; Imidazoles; Mice; Mice, Inbred NOD; Mice, SCID; Organophosphorus Compounds; Phosphorylation; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2011 |
Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Regression Analysis; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Middle Aged; Neoplasm Metastasis; Osteonecrosis; Pamidronate; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2011 |
Number needed to treat is incorrect without proper time-related considerations.
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; Data Interpretation, Statistical; Diphosphonates; Evidence-Based Medicine; Female; Follow-Up Studies; Herpes Simplex; Humans; Imidazoles; Kaplan-Meier Estimate; Life Tables; Periodicals as Topic; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Sample Size; Survival Rate; Time Factors; Valacyclovir; Valine; Zoledronic Acid | 2012 |
Subtrochanteric fracture in a patient receiving zoledronic acid therapy for metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Stress; Hip Fractures; Humans; Imidazoles; Middle Aged; Zoledronic Acid | 2011 |
Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lasers, Semiconductor; Low-Level Light Therapy; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Platelet-Rich Plasma; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Outcome; Zoledronic Acid | 2012 |
A case of femoral diaphyseal fracture after long-term treatment with zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diaphyses; Diphosphonates; Female; Femoral Fractures; Humans; Imidazoles; Middle Aged; Time Factors; Zoledronic Acid | 2015 |
Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Databases, Factual; Diphosphonates; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Insurance Claim Review; Medicare Part C; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Spinal Cord Compression; United States; Zoledronic Acid | 2012 |
Lip ulceration associated with intravenous administration of zoledronic acid: report of a case.
Topics: Analgesics; Antidepressive Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Lip Diseases; Middle Aged; Osteonecrosis; Ulcer; Zoledronic Acid | 2012 |
[Renal insufficiency and breast cancer].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Creatinine; Dehydration; Diphosphonates; Female; Glomerular Filtration Rate; Humans; Imidazoles; Kidney; Middle Aged; Renal Insufficiency; Young Adult; Zoledronic Acid | 2012 |
Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Middle Aged; Pamidronate; Retrospective Studies; Zoledronic Acid | 2012 |
Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells.
Topics: Animals; Apoptosis; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mice; Mice, Nude; Xenograft Model Antitumor Assays; Zoledronic Acid | 2011 |
Krüppel-like factors KLF2 and 6 and Ki-67 are direct targets of zoledronic acid in MCF-7 cells.
Topics: Apoptosis; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Diphosphonates; Female; Humans; Imidazoles; Ki-67 Antigen; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors; Proto-Oncogene Proteins; Zoledronic Acid | 2012 |
The case of the overlooked osteoclasts.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Monitoring; Female; Humans; Imidazoles; Middle Aged; Zoledronic Acid | 2011 |
AZURE subgroup analysis shows adjuvant therapy with zoledronic acid may benefit breast cancer patients postmenopausal >5 years.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Postmenopause; Zoledronic Acid | 2011 |
Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Blotting, Western; Bone Resorption; Breast Neoplasms; Cell Proliferation; Diphosphonates; Female; Fibronectins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; MCF-7 Cells; Microarray Analysis; Real-Time Polymerase Chain Reaction; Thrombospondin 1; Transforming Growth Factor beta1; Up-Regulation; Zoledronic Acid | 2012 |
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Markov Chains; Prostatic Neoplasms; Quality-Adjusted Life Years; United States; Zoledronic Acid | 2012 |
Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Female; Humans; Imidazoles; Quality of Life; Quality-Adjusted Life Years; Zoledronic Acid | 2012 |
Activation of BK(Ca) channels in zoledronic acid-induced apoptosis of MDA-MB-231 breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Humans; Imidazoles; Large-Conductance Calcium-Activated Potassium Channel alpha Subunits; Membrane Potential, Mitochondrial; Zoledronic Acid | 2012 |
Breast cancer cell targeting by prenylation inhibitors elucidated in living animals with a bioluminescence reporter.
Topics: Alkyl and Aryl Transferases; Animals; Benzamides; Blotting, Western; Bone Density Conservation Agents; Breast Neoplasms; Cell Line, Tumor; Clodronic Acid; Diphosphonates; Female; Genes, Reporter; Green Fluorescent Proteins; HEK293 Cells; Humans; Imidazoles; Luciferases; Luminescent Measurements; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Microscopy, Confocal; Mutation; Protein Prenylation; Recombinant Fusion Proteins; Transplantation, Heterologous; Zoledronic Acid | 2012 |
Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.
Topics: Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Female; Health Care Costs; Humans; Imidazoles; Markov Chains; Models, Economic; Multivariate Analysis; Outcome Assessment, Health Care; United States; Zoledronic Acid | 2012 |
Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Disease Progression; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Transcriptome; Zoledronic Acid | 2012 |
A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Fanconi Syndrome; Female; Humans; Imidazoles; Middle Aged; Nephritis, Interstitial; Zoledronic Acid | 2012 |
Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Breast Neoplasms; Diphosphonates; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Inhibitory Concentration 50; Primary Cell Culture; Zoledronic Acid | 2012 |
Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Case-Control Studies; Cell Proliferation; Cytokines; Diphosphonates; Endothelial Cells; Female; Gingival Crevicular Fluid; Humans; Hydroxymethylglutaryl CoA Reductases; Imidazoles; Injections, Intravenous; Interleukin-6; Male; Middle Aged; Mouth Mucosa; Multiple Myeloma; Osteoclasts; Osteoprotegerin; RANK Ligand; Statistics, Nonparametric; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid.
Topics: Blotting, Western; Bone Density Conservation Agents; Breast Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; Diphosphonates; Extracellular Matrix; Extracellular Matrix Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Wound Healing; Zoledronic Acid | 2012 |
Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Imidazoles; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Middle Aged; Multivariate Analysis; Pamidronate; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2012 |
Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Denosumab; Diphosphonates; Female; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; RANK Ligand; Xenograft Model Antitumor Assays; Zoledronic Acid | 2012 |
Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Middle Aged; Quality of Life; Retrospective Studies; Socioeconomic Factors; Zoledronic Acid | 2013 |
Characterization of clinical course and usual care patterns in female metastatic breast cancer patients treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Diphosphonates; Disease Progression; Female; Fractures, Spontaneous; Humans; Imidazoles; Middle Aged; Musculoskeletal Pain; Palliative Care; Retrospective Studies; Treatment Outcome; Young Adult; Zoledronic Acid | 2013 |
Zoledronic acid-induced expansion of γδ T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells.
Topics: Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Interleukin-18; Killer Cells, Natural; Leukocytes, Mononuclear; Middle Aged; Neoplasm Staging; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes, Helper-Inducer; Zoledronic Acid | 2013 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid | 2012 |
Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
Topics: Aged; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Osteolysis; Peptides; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2013 |
Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Diphosphonates; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Molecular Structure; Oligopeptides; Osteoclasts; Osteoporosis; Xenograft Model Antitumor Assays; Zoledronic Acid | 2013 |
Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction.
Topics: Adult; Aged; Aged, 80 and over; Attitude of Health Personnel; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Feasibility Studies; Female; Fractures, Bone; Home Infusion Therapy; Humans; Imidazoles; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Nurses, Community Health; Osteonecrosis; Patient Compliance; Patient Satisfaction; Physicians; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid | 2013 |
NICE guidance on denosumab for prevention of skeletal-related events in adults with bone metastases from solid tumours.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Prostatic Neoplasms; Zoledronic Acid | 2012 |
Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Cancer Care Facilities; Diphosphonates; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Middle Aged; Pamidronate; Registries; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2013 |
Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cathepsin K; Cell Line, Tumor; Coculture Techniques; Collagen Type I; Diphosphonates; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Integrin beta3; Macrophage Colony-Stimulating Factor; Models, Biological; Neoplasm Metastasis; Osteoclasts; Osteolysis; RANK Ligand; Zoledronic Acid | 2013 |
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects.
Topics: Bone Resorption; Breast Neoplasms; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Cyclooxygenase 2; Dinoprostone; Diphosphonates; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Imidazoles; Isoenzymes; Membrane Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Osteolysis; Prostaglandin-Endoperoxide Synthases; rhoA GTP-Binding Protein; Tumor Cells, Cultured; Zoledronic Acid | 2003 |
Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diphosphonates; Docetaxel; Genes, erbB-2; Humans; Imidazoles; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Taxoids; Transfection; Zoledronic Acid | 2003 |
Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
Topics: Bone Resorption; Breast Neoplasms; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; Imidazoles; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Pamidronate; Quality of Life; Recurrence; Zoledronic Acid | 2004 |
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Letrozole; Magnetic Resonance Imaging; Middle Aged; Nitriles; Pamidronate; Pilot Projects; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2004 |
Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Topics: Animals; Apoptosis; Blotting, Western; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Separation; Cell Survival; Diphosphonates; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Imidazoles; Luciferases; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Neoplasm Invasiveness; Neoplasm Metastasis; Osteoclasts; Time Factors; Zoledronic Acid | 2004 |
Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fluorouracil; Humans; Imidazoles; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Salvage Therapy; Tamoxifen; Zoledronic Acid | 2004 |
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells.
Topics: Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Diphosphonates; Diterpenes; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Mevalonic Acid; Prostatic Neoplasms; Time Factors; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosphamide; Diphosphonates; Docetaxel; Drug Synergism; Epirubicin; Female; Fluorouracil; Humans; Ibandronic Acid; Imidazoles; In Vitro Techniques; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Taxoids; Zoledronic Acid | 2004 |
Zoledronic acid-associated thrombotic thrombocytopenic purpura.
Topics: Breast Neoplasms; Diphosphonates; Female; Hemolytic-Uremic Syndrome; Humans; Imidazoles; Middle Aged; Purpura, Thrombocytopenic; Zoledronic Acid | 2004 |
Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
Topics: Ambulatory Care; Bone Neoplasms; Breast Neoplasms; Costs and Cost Analysis; Diphosphonates; Female; Hospitalization; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Diphosphonates; Female; Humans; Imidazoles; Interferon-gamma; Neovascularization, Pathologic; Prospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2005 |
[Rapid drug information].
Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Information Services; Germany; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Risk Assessment; Zoledronic Acid | 2005 |
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Metastasis; Pamidronate; Quality of Life; State Medicine; United Kingdom; Zoledronic Acid | 2005 |
Special precautions.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; Diphosphonates; Fatal Outcome; Female; Humans; Imidazoles; Maxillary Diseases; Osteonecrosis; Zoledronic Acid | 2005 |
Ask us: Some drugs affect tooth movement.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Remodeling; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoclasts; Tooth Movement Techniques; Zoledronic Acid | 2005 |
Costs and consequences of using pamidronate compared with zoledronic acid in the management of breast cancer patients in the UK.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Calcium Metabolism Disorders; Chemoprevention; Cost-Benefit Analysis; Decision Support Techniques; Diphosphonates; Female; Health Care Costs; Humans; Imidazoles; Middle Aged; Pamidronate; State Medicine; United Kingdom; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Breast Neoplasms; Dental Care; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Risk Factors; Zoledronic Acid | 2005 |
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Topics: Aged; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease Progression; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Pamidronate; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid | 2005 |
Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.
Topics: Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Movement; Cell Proliferation; Collagen; Diphosphonates; Doxorubicin; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imidazoles; In Vitro Techniques; Laminin; Neoplasm Invasiveness; Proteoglycans; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Reversible metastatic visceral calcification detected by 99mTc-methylene diphosphonate bone scanning in breast cancer.
Topics: Antineoplastic Agents; Bone and Bones; Breast Neoplasms; Calcification, Physiologic; Calcium; Diphosphonates; Female; Heart Neoplasms; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Technetium Tc 99m Medronate; Thyroid Neoplasms; Time Factors; Zoledronic Acid | 2005 |
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspase 3; Caspase 7; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Clodronic Acid; Diphosphonates; Energy Metabolism; Female; Humans; Imidazoles; Inhibitory Concentration 50; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Middle Aged; Pamidronate; Quality-Adjusted Life Years; United Kingdom; Zoledronic Acid | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Dental Caries; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hyperostosis; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Osteoporosis; Pamidronate; Periodontitis; Prostatic Neoplasms; Risk Factors; Tooth Extraction; Zoledronic Acid | 2005 |
Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Mandibular Diseases; Maxillary Diseases; Multiple Myeloma; Osteomyelitis; Osteonecrosis; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Greece; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prospective Studies; Prostatic Neoplasms; Risk Factors; Time Factors; Treatment Failure; Zoledronic Acid | 2005 |
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Male; Mice; Mice, Nude; Prostatic Neoplasms; Proteins; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays; Zoledronic Acid | 2005 |
Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Osteoporosis; Uveitis, Anterior; Zoledronic Acid | 2005 |
Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mandible; Mandibular Diseases; Osteonecrosis; Radiography; Tooth Extraction; Wound Healing; Zoledronic Acid | 2005 |
Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Tooth Extraction; Zoledronic Acid | 2006 |
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Pain; Palliative Care; Prostatic Neoplasms; Strontium Radioisotopes; Time Factors; Treatment Outcome; Zoledronic Acid | 2006 |
[Two cases of stage IV breast cancer with severe hypercalcemia].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Goserelin; Humans; Hypercalcemia; Imidazoles; Leuprolide; Lymph Nodes; Lymphatic Metastasis; Paclitaxel; Quality of Life; Tamoxifen; Zoledronic Acid | 2006 |
Jaw complications in breast and prostate cancer patients treated with zoledronic acid.
Topics: Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Prostatic Neoplasms; Zoledronic Acid | 2006 |
Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; BRCA1 Protein; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Imidazoles; Mevalonic Acid; Mutation; Paclitaxel; Signal Transduction; Time Factors; Zoledronic Acid | 2006 |
Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy.
Topics: Aged; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Periodontitis; Zoledronic Acid | 2006 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid | 2007 |
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Diphosphonates; DNA Fragmentation; Drug Antagonism; Drug Synergism; Epirubicin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid | 2006 |
Bisphosphonate-associated arthritis.
Topics: Arthritis; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Fatal Outcome; Female; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Middle Aged; Pamidronate; Zoledronic Acid | 2006 |
In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cell Survival; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Radiotherapy; Zoledronic Acid | 2006 |
Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Topics: Adult; Aged; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Histiocytosis, Langerhans-Cell; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Magnetic Resonance Imaging; Male; Mandible; Mandibular Diseases; Maxilla; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Radiography, Panoramic; Radionuclide Imaging; Retrospective Studies; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2006 |
A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss.
Topics: Acute-Phase Reaction; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Incidence; Osteoporosis; Zoledronic Acid | 2007 |
Zoledronic acid palliation in bone-metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase II as Topic; Diphosphonates; Female; Humans; Imidazoles; Pain; Zoledronic Acid | 2006 |
Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Creatinine; Diphosphonates; Drug Administration Schedule; Drug Costs; Female; Health Care Costs; Humans; Imidazoles; Infusions, Intravenous; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Pamidronate; Prevalence; Registries; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Multiple Myeloma; Necrosis; Osteonecrosis; Pamidronate; Tomography, X-Ray Computed; Zoledronic Acid | 2007 |
Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Mastectomy; Middle Aged; Osteonecrosis; Radiotherapy; Zoledronic Acid | 2006 |
Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: Report of 3 cases.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Platelet-Rich Plasma; Tooth Extraction; Zoledronic Acid | 2007 |
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid | 2007 |
Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Italy; Male; Middle Aged; Pain Measurement; Pilot Projects; Prostatic Neoplasms; Zoledronic Acid | 2007 |
Non-inferiority trial design for recurrent events.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Computer Simulation; Diphosphonates; Female; Humans; Imidazoles; Models, Statistical; Research Design; Sample Size; Zoledronic Acid | 2007 |
Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Models, Animal; Doxycycline; Drug Synergism; Female; Humans; Imidazoles; Mice; Mice, Nude; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2007 |
Zoledronic acid prevents bone loss.
Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Zoledronic Acid | 2007 |
Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer.
Topics: Animals; Bone Density Conservation Agents; Breast Neoplasms; Coronary Artery Disease; Diphosphonates; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Myocardial Infarction; Risk Factors; Zoledronic Acid | 2007 |
An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Hospitals; Humans; Imidazoles; Infusions, Intravenous; Medical Audit; Pamidronate; Time Factors; United Kingdom; Zoledronic Acid | 2007 |
Bone density in breast cancer: when to intervene?
Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Goserelin; Humans; Imidazoles; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2007 |
Effect of zoledronic acid and an antibody against bone sialoprotein II on MDA-MB-231(GFP) breast cancer cells in vitro and on osteolytic lesions induced in vivo by this cell line in nude rats.
Topics: Animals; Antibodies; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Green Fluorescent Proteins; Humans; Imidazoles; In Vitro Techniques; Male; Osteolysis; Rats; Rats, Nude; Sialoglycoproteins; Zoledronic Acid | 2007 |
Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws.
Topics: Aged; Aged, 80 and over; Alveolar Process; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Radiography; Severity of Illness Index; Zoledronic Acid | 2007 |
A novel case of bisphosphonate-related osteonecrosis of the torus palatinus in a patient with metastatic breast cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Exostoses; Female; Humans; Imidazoles; Maxilla; Middle Aged; Osteonecrosis; Palate, Hard; Zoledronic Acid | 2006 |
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Case-Control Studies; Cathepsin K; Cathepsins; Cystatin C; Cystatins; Diphosphonates; Disease Progression; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Prostatic Hyperplasia; Prostatic Neoplasms; ROC Curve; Zoledronic Acid | 2008 |
The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates.
Topics: Adenocarcinoma; Bone Neoplasms; Bone Plates; Bone Screws; Breast Neoplasms; Cutaneous Fistula; Diphosphonates; Female; Humans; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Necrosis; Oral Fistula; Osteolysis; Osteomyelitis; Pamidronate; Prostatic Neoplasms; Recurrence; Tomography, X-Ray Computed; Zoledronic Acid | 2008 |
Treating bisphosphonate osteonecrosis of the jaws: is there a role for resection and vascularized reconstruction?
Topics: Bone Density Conservation Agents; Bone Plates; Bone Transplantation; Breast Neoplasms; Carcinoma; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Osteonecrosis; Pamidronate; Plastic Surgery Procedures; Surgical Flaps; Zoledronic Acid | 2007 |
Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bone and Bones; Breast Neoplasms; Calcium; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Synergism; Female; Humans; Ibandronic Acid; Imidazoles; Zoledronic Acid | 2008 |
Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases.
Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Kidney; Longitudinal Studies; Male; Middle Aged; Time Factors; Zoledronic Acid | 2008 |
Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fibroblast Growth Factor 2; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2008 |
Reply to the article "oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171).
Topics: Administration, Oral; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Collagen Type I; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Osteocalcin; Peptides; Procollagen; Prognosis; Sensitivity and Specificity; Zoledronic Acid | 2008 |
Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Jaw Diseases; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Tomography, Spiral Computed; Tooth Extraction; Water; Zoledronic Acid | 2008 |
Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer.
Topics: Acute Disease; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Scleritis; Uveitis, Anterior; Zoledronic Acid | 2008 |
[Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Injections, Intravenous; Pamidronate; Zoledronic Acid | 2008 |
Osteonecrosis of the jaw.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Middle Aged; Osteonecrosis; Penicillin V; Risk Factors; Tooth Extraction; Zoledronic Acid | 2008 |
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cystatin C; Diphosphonates; Female; Humans; Imidazoles; Interleukin-6; Male; Middle Aged; Osteoporosis; Prostate-Specific Antigen; Prostatic Neoplasms; ROC Curve; Zoledronic Acid | 2009 |
Effects of two novel bisphosphonates on bone cells in vitro.
Topics: Animals; Bone and Bones; Bone Resorption; Breast Neoplasms; Cell Count; Cells, Cultured; Culture Media, Conditioned; Diphosphonates; DNA; Dose-Response Relationship, Drug; Edetic Acid; Female; Humans; Imidazoles; Osteoblasts; Osteoclasts; Pamidronate; Rats; Tumor Cells, Cultured; Zoledronic Acid | 1994 |
Research on bone metastases quickens its pace.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Neoplasm Proteins; Palliative Care; Parathyroid Hormone-Related Protein; Proteins; Zoledronic Acid | 1997 |
Bisphosphonates induce apoptosis in human breast cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Cell Nucleus; Cell Survival; Clodronic Acid; Diphosphonates; DNA Fragmentation; Female; Humans; Imidazoles; Kinetics; Pamidronate; Pyrrolidines; Tumor Cells, Cultured; Zoledronic Acid | 2000 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |
Bisphosphonates induce breast cancer cell death in vitro.
Topics: Amino Acid Chloromethyl Ketones; Annexins; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase Inhibitors; Caspases; Cell Death; Cell Nucleus; Clodronic Acid; Cysteine Proteinase Inhibitors; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Ibandronic Acid; Imidazoles; Kinetics; Pamidronate; Tumor Cells, Cultured; Zoledronic Acid | 2000 |
Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Male; Osteoclasts; Osteoporosis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2000 |
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Count; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Mevalonic Acid; Paclitaxel; Time Factors; Tumor Cells, Cultured; Zoledronic Acid | 2001 |
Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Green Fluorescent Proteins; Humans; Imidazoles; Luminescent Proteins; Mice; Mice, Nude; Microscopy, Fluorescence; Osteolysis; Recombinant Proteins; Tumor Cells, Cultured; Zoledronic Acid | 2001 |
The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Caspases; Cell Membrane; Cytochrome c Group; Diphosphonates; Female; Genes, ras; Humans; Imidazoles; Protein Prenylation; ras Proteins; Tumor Cells, Cultured; Zoledronic Acid | 2002 |
Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.
Topics: Bone and Bones; Breast Neoplasms; Cell Differentiation; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Imidazoles; Lovastatin; Mevalonic Acid; Osteoblasts; Pregnancy; Structure-Activity Relationship; Tumor Cells, Cultured; Zoledronic Acid | 2002 |